The Role of N-Methyl D-Aspartate Receptors in the Development of the Human Cerebral Cortex by Bagasrawala, Inseyah
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
8-24-2016
The Role of N-Methyl D-Aspartate Receptors in
the Development of the Human Cerebral Cortex
Inseyah Bagasrawala
University of Connecticut - Storrs, inseyah.bagasrawala@gmail.com
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Bagasrawala, Inseyah, "The Role of N-Methyl D-Aspartate Receptors in the Development of the Human Cerebral Cortex" (2016).
Doctoral Dissertations. 1239.
https://opencommons.uconn.edu/dissertations/1239
 The Role of N-Methyl D-Aspartate Receptors in the Development of  
the Human Cerebral Cortex 
  
Inseyah Shabbir Bagasrawala, Ph.D. 
University of Connecticut, 2016 
Abstract 
N-Methyl D-Aspartate receptors (NMDARs), a subtype of glutamate receptors, are important in 
neural development. The distribution and function of these receptors are well-studied in rodent 
and adult human brains, but far less is known about NMDARs in the human fetal cerebral cortex. 
The human cerebral cortex develops from multipotent neural progenitors called the radial glia 
cells (RGCs) that give rise to intermediate and interneuron progenitors, neurons, and glial cells. 
In my thesis, I studied the distribution of NMDAR subunits, NR1, NR2A and NR2B, in the human 
cerebral cortex from 10 to 24 gestational weeks (gw), a period of intense neurogenesis and 
synaptogenesis. Moreover, I studied the effects of kynurenic acid (KYNA), a neuroactive 
metabolite of tryptophan degradation that acts as an endogenous NMDAR antagonist. Elevated 
levels of KYNA have been observed in pregnant women after viral infections and in the 
cerebrospinal fluid of adult schizophrenic patients. In my thesis work, I used an in vitro system of 
RGCs enriched from the human cerebral cortex between 16 and 19 gw to study the potential 
impact of KYNA-induced NMDAR blockade in human corticogenesis. qPCR, in situ hybridization, 
Western blotting, and double immunolabeling experiments revealed the presence of mRNA and 
proteins of the NMDAR subunits in cortical progenitors and post-mitotic neurons along the 
telencephalic wall suggesting possible roles for NMDARs in progenitor proliferation, cell-fate 
determination, and neuronal differentiation. This was, in fact, observed in the in vitro study where 
blocking NMDARs either with D-amino phosphovalerate (D-APV) or KYNA significantly 
decreased survival, proliferation, specification and neuronal differentiation of RGCs, and 
increased the number of reactive astrocytes, and levels of the pro-inflammatory cytokine IL-6, 
activating the Jak-STAT signaling pathway. These results suggest a NMDAR-dependent 
mechanism for impairment of cortical circuitry formation in the human fetal brain.  
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Chapter 1: 
 
Introduction 
 
Development of the cerebral cortex 
 
The mammalian neocortex has evolved during evolution, and thus, the shape, size, 
and neuron number in the cerebral cortex of different mammalian species vary widely (Hill 
and Walsh, 2005). These differences are in a large part due to the organization and 
behavior of neural progenitor cells during embryonic development. Most of our 
understanding of neocortical development is based on observations made from cellular 
and molecular studies of the mouse and rat. Although these species have neocortices 
that exhibit many of the key features general to all mammals, including a six-layered 
cortical organization and regionalization into cortical areas, they lack the increased folding 
and complexity of the cerebral cortex, possessed by higher mammals (Zecevic, 1993; Hill 
and Walsh, 2005). In contrast to the very large and highly folded (gyrencephalic) 
neocortex of Homo sapiens (man), the surface area of rodent neocortex is 1000 times 
smaller and non-folded (lissencephalic). This major morphological difference translates 
into a deeper significant functional difference in the process of neocortical development. 
Thus, in addition to rodents, the most used animal model, we also need to study primate 
brains.  
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 Wilhelm His, and subsequently Magini, Cajal, and Golgi, observed that 
development of the human neocortex depends on germinal cells known as 
“spongioblasts” that line the ventricular surface of the neural tube, capable of rapid cell 
divisions giving rise to both neurons and glia (His, 1880; Rakic, 1971). These 
“spongioblasts”, now universally known as the radial glia cells (RGCs), have a cell body 
situated in the ventricular epithelium with a short process attached to the ventricular 
surface and a long fiber that extends to the pial surface. The newly born neurons migrate 
intimately apposed to these RGC fibers that form scaffolds for the radial neuronal 
migration (Rakic, 1972). Further studies on cortical development gave rise to the radial 
unit and proto-map hypothesis (Rakic, 1988), which states that the same ontogeny 
(progeny of a given ventricular neuronal progenitor) migrates on a continuous RGC fiber 
to the cortical plate, forming a radial column of cells that are functionally related, and this 
organization of cells project a ventricular proto-map onto the developing cortex (Rakic, 
2009). 
 
In addition to form a scaffold for neuronal migration, RGCs represent a transient 
population of precursor cells present in the cortical ventricular zone (VZ) at the beginning 
of neurogenesis (~6 gw) (Zecevic, 2004; Lui et al., 2011). Many years of dedicated 
research resulted in our view today that RGCs are multipotent progenitors capable of 
generating all other neural cell types in rodents (Malatesta et al., 2000; Noctor et al., 2001, 
Tamamaki et al., 2001), and humans (Howard et al., 2008; Mo et al., 2007, 2009; Hansen 
et al., 2010; Yu and Zecevic, 2011; Lui et al., 2011). In humans, RGCs in the dorsal  
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telencephalon consist of two major subclasses, outer or basal RGCs (oRGCs) that have 
only a single basal fiber, and ventricular or apical RGCs (vRGCs) that have a short apical 
fiber and a long basal fiber. Cell bodies of vRGCs situated in the VZ, while those of 
oRGCs are located in the SVZ (Rakic, 1971; Haubensak, et al., 2004; Noctor et al., 2004; 
Hansen et al., 2010; Lui et al., 2011). vRGCs and oRGCs express different sets of genes 
(Pollen et al., 2015). For example, in the human telencephalic wall at 17 gw, vRGCs 
express the transcription factor Pax6, while oRGCs express another transcription factor 
Hopx (Figure 1). vRGCs undergo symmetric divisions to enlarge the progenitor pool, and 
asymmetric divisions giving rise to both, progenitors and neurons (Malatesta et al., 2000; 
Noctor et al., 2001, 2004). Some of these progenitor daughter cells migrate to the outer 
subventricular zone (oSVZ), which lies above the VZ, and transform into oRGCs (Hansen 
et al., 2010; Lui et al., 2011). oRGCs or basal progenitors undergo asymmetric divisions 
giving an intermediate progenitor and a neuron (Lui et al., 2011). The intermediate 
progenitors can undergo multiple rounds of self-renewal causing a trans-amplification of 
the progenitor pool before undergoing a terminal division to give two neurons. This 
expansion of progenitors in the human oSVZ lasts for several months and provides for 
the increased neuron production that is highly relevant for building a larger human brain 
(Noctor et al., 2004; Kriegstein et al., 2006; Lui et al., 2011; Zecevic et al., 2011, Radonjic 
et al., 2014).   
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Figure 1. Immunolabeling of two types of RGC in coronal sections of the human fetal 
cerebral cortex at 17 gw. vRGCs express Pax6 (red), a transcription factor expressed 
during development (left), and oRGCs express Hopx (red), a transcription factor labelling 
this subset of the primate-specific multipotent neural progenitor cells (right). Nuclei are 
labeled with bis-benzimide (BB) in blue. 
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Radial glial fibers in gyrencephalic brains of primates diverge to form a fanned 
array by the time they reach the pia (Kriegstein et al., 2006, Lui et al., 2011). Fibers of 
RGCs are used as scaffolds by migrating neurons to reach the developing cortical plate 
(CP) from their birthplace in the VZ or oSVZ (Rakic, 1972, 2009; Reillo et al., 2011). 
Neuronal migration ultimately gives rise to the six-layered neocortex in an inside-out 
fashion with the earliest migrated neurons forming layer VI, and the ones that migrate last 
form layer II-III (layer I is present from the start and almost devoid of neuronal cell bodies) 
(Rakic, 1971, 1972; Rakic et al., 1986; Bystron et al., 2008,  Zecevic et al., 2011). In 
humans, gestation period is 40 weeks long and at midgestation (~20 gw) several 
important developmental processes are taking place. Synaptogenesis begins and the 
upper cortical layers are forming. Neurons from these upper layers play a crucial role in 
establishing cortico-cortical connections and development of higher brain functions that 
characterize humans (Zecevic, 1998; Hill and Walsh, 2005). One important difference 
between human and rodent brains is the origin of cortical interneurons. In human the 
cortical interneurons are derived from RGCs in both ventral (ganglionic eminence) and 
dorsal (cortical VZ/SVZ) telencephalic regions. Dorsally derived cortical interneurons 
could be more vulnerable to alterations in the growth environment during development 
and could be selectively eliminated. This would result in abnormal cortical circuitry, which 
indeed is a hallmark of neurodevelopmental disorders, including schizophrenia, epilepsy 
or autism spectrum disorder (Bayatti et al., 2008; Clowry et al., 2010; Sessa et al., 2008; 
Zecevic et al., 2011; Jakovcevski et al., 2011, Radonjic et al., 2014). Therefore, studying  
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 factors that can affect the proliferation of the dorsal RGCs and their differentiation into 
cortical neurons is clinically significant for better understanding not only the normal 
development but also the underlying pathophysiology of psychiatric diseases. 
 
Gliogenesis 
 
Gliogenesis is the generation of glia populations derived from the multipotent RGC 
progenitors. After giving rise to the majority of neuronal populations, the remaining RGCs 
undergo subsequent differentiation giving rise to cells of the glial lineage. RGCs generate 
both astrocytes and oligodendrocytes in human cortical development (Mo et al., 2007, 
2009; Yu and Zecevic, 2011; Jakovcevski et al., 2011). Astrocytes are responsible for 
modulating the chemical microenvironment by modulating growth factor transport and 
uptake, altering ion gradients, and neurotransmitter transduction during corticogenesis. 
Oligodendrocytes are a highly specialized group of glia cells that produce myelin, which 
facilitate saltatory conduction of action potentials by insulating the entire lengths of axons. 
 
 Inflammation is one of the first defense mechanisms of the innate immune system 
to infection and other physiological insults such as tissue damage or stress (Gallin et al., 
1999). Cytokines are small molecules important for cell signaling with a wide-ranging 
roles in the innate and adaptive immune systems, where they help regulate the 
recruitment and activation of immune cells, induce cell apoptosis, and inhibit protein 
synthesis (Curfs et al., 1997). Astrocytes and microglia are the major immunocompetent  
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cells in the CNS. They regulate both the induction and limitation of inflammatory 
processes in the CNS by synthesizing various cytokines like IL-6 and IL-10, and by 
regulating the expression of various cell surface receptors such as pathogen recognition 
receptors, cytokine receptors, and numerous receptors crucial for antigen presentation 
synthesis of (Seth & Koul, 2008; Ransohoff & Perry, 2009).  
 
It has been considered for a long time that the main role of astrocytes is related to 
neuronal support functions. However, accumulating evidence suggests that astrocytes 
exert a much wider spectrum of functions, including regulation of neuronal differentiation, 
axonal guidance, synapse formation, and brain plasticity (Seth & Koul, 2008). During an 
insult to the cellular environment, there is astrocytic hypertrophy, a huge increase in 
astrocyte number leading to gliosis, and an increase in the expression of S100β, a protein 
that is involved in a variety of neuronal and glial signaling mechanisms (Meyer et al., 
2011). It has been suggested that the neuro-inflammatory pathology in schizophrenia 
involves gliosis. Indeed, one well-established finding in this context is the increase in 
serum and/or cerebrospinal fluid levels of S100β in schizophrenia (Rothermundt et al., 
2009).  
 
NMDARs in cortical development 
 
RGCs, in rodents, are influenced by the major excitatory and inhibitory 
neurotransmitters, glutamate and GABA, respectively (LoTurco et al., 1995; Haydar et  
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 al., 2000; Letinic et al., 2002; Matta et al., 2013). Glutamate can increase 
progenitor proliferation in the VZ while having opposite effects in the SVZ of the mouse 
embryonic cerebral cortex (Haydar et al., 2000). During rodent cortical development 
glutamate promotes neuronal differentiation, by modulating the cell cycle length of the 
progenitors in the SVZ (LoTurco et al., 1995). Both neurogenesis and neuronal migration 
have been shown to be NMDAR-dependent in rodent hippocampal development (Manent 
et al., 2005; Toriumi et al., 2012). Glutamate exerts these effects through the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPARs) and kainate receptors 
(Lu et al., 2001; Matta et al., 2013). However, recent investigations in human pluripotent 
and human embryonic stem cell derived neurons have attributed these effects of 
glutamate to NMDARs (Gupta et al., 2000; Suzuki et al., 2006).  
 
NMDARs are ligand-gated and voltage-gated ionotropic glutamate receptors 
composed of four subunits (two NR1 and two NR2 or NR3 subunits). The NR2 subunit 
possesses four isoforms A, B, C, and D, whose expression is developmentally regulated, 
with each isoform providing specific physiological features to the complete NMDAR (Cull-
Candy et al., 2001) (Figure 2). Glutamate released from cells of the cerebral wall affects 
RGC proliferation non-synaptically (Suzuki et al., 2006) through NMDARs, whose 
activation increases the intracellular concentration of calcium, a secondary messenger 
involved in downstream signaling (Haydar et al., 2000; Marin et al., 2001; Li et al., 2015). 
Several findings have suggested physiologically relevant interactions between 
corticogenesis and NMDAR function (Blanton et al., 1990; LoTurco et al., 1991, 1995;  
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 Figure 2. The NMDAR is a membrane-spanning heteromeric glutamate receptor 
consisting of the obligatory NR1 subunit and any of the four isoforms (A, B, C, D) of the 
NR2 subunit. The NR2 subunit binds to the ligand glutamate, while the NR1 subunit binds 
to the co-agonist glycine. 
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 Haydar et al., 2000; Reiprich et al., 2005; Li et al., 2015). These studies were performed 
in rodents at the neonatal stage which corresponds to the human midgestation (20 gw), 
the developmental period studied here. 
 
During embryonic and early postnatal development in rodents, NMDARs 
containing mainly NR1, NR2B, NR2D, and NR3A are present throughout the brain (Cull-
Candy et al., 2001; Henson et al., 2008). The expression of NR2B, NR2D, and NR3A 
decreases during maturation, while NR2A and/or NR2C become more abundant 
(Watanabe et al., 1992; Ciabarra et al., 1995; Laurie et al., 1997; Wenzel et al., 1997). 
Arguably, the most studied developmental change in NMDARs is the switch from NR2B-
containing NMDARs to NR2A-containing NMDARs noted during maturation of excitatory 
synapses. In rodents, a change of the major membrane-associated guanylate kinase 
(MAGUK) at the postsynaptic end from SAP102 to PSD-95 parallels this change from 
NR2B to NR2A subunits of NMDARs. In the adult synapse, NR2A is the most prevalent 
form although NR2B is still found; PSD-95 is the prevalent MAGUK even though SAP102 
remains (Sans et al., 2005; van Zundert et al., 2004; Petralia et al., 2005). 
 
The importance of the correct expression of NMDAR subunits is seen upon 
ablation of the obligatory subunit NR1 during rodent development. Normal maturation of 
the hippocampal circuitry is disrupted resulting in schizophrenia-like cognitive decline and 
behavioral deficits later in adulthood (Rodenas-Ruano et al., 2012). The pathophysiology 
for most of these disorders essentially remains unknown. Improper functioning of  
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NMDARs during development, particularly of those expressed in the primate-specific 
dorsal RGCs and cortical interneurons, could lead to the formation of an aberrant cortical 
circuitry in adulthood, possibly explaining the developmental etiology of most of the 
human neuropsychiatric disorders. The NMDARs undoubtedly play significant roles in 
maintaining a balance between cortical excitation and inhibition, synaptic plasticity, and 
learning and memory (Malenka et al., 1993; Paoletti et al., 2013). However, there is a lack 
of knowledge regarding the distribution, subunit composition, and role of NMDARs in 
human cortical progenitors during corticogenesis. To better understand the role of 
NMDARs in human corticogenesis we propose to study the effects of NMDAR subunit 
specific blockade in RGC cultures established from the human fetal cortex at midgestation 
(16 gw to 23 gw). 
 
Kynurenic acid (KYNA) in cortical development 
 
KYNA was identified as a constituent of canine urine (hence its name) as early 
as1853 (Liebig, 1853). In the early part of this century, KYNA was recognized as a side 
product of tryptophan metabolism in mammals (Ellinger, 1904) (Figure 3), but no 
particular biological function was suggested until 1982, when its neuro-inhibitory potency 
was discovered in neurophysiological experiments in rat cortical neurons (Perkins and 
Stone, 1982). Studies from several laboratories soon established a unique pharmacologic 
profile of KYNA: KYNA is an antagonist to ionotropic excitatory receptors, namely, the 
nicotinic acetylcholine receptors (nAChRs), and NMDARs in the rodent brain (Stone et  
11 
  
Figure 3. KYNA is a by-product of tryptophan metabolism, with kynurenine 
aminotransferase (KAT) functioning as the rate-limiting enzyme. 
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al., 1989). Subsequent receptor binding and physiological studies in rodents 
demonstrated that KYNA can also competitively act, with higher potency (Kd -8 μM), at 
the glycine site associated with the NMDAR complex (Kessler et al., 1989). This site, 
which is clearly essential for receptor function, appears to constitute a primary target of 
KYNA (Kleckner and Dingledine, 1988). Conceivably, KYNA can therefore exert control 
over NMDAR activity, particularly when the modulatory site is not saturated with glycine. 
KYNA was first reported in the mammalian brain in 1988 (Moroni et al., 1988; Turski et 
al., 1989) with tissue concentrations (1- 5 nM) varying between brain regions and, more 
dramatically, between species. The rat brain, for example, contains 10 times less KYNA 
than the human brain. Levels of KYNA in the brain increase with age, so that the cerebral 
cortex of a 2-year old rat has 10 times more KYNA than a 2-month old rat (Moroni et al., 
1989). The concentration of KYNA found extracellularly in the rat brain and in the human 
cerebrospinal fluid (CSF), as determined by microdialysis, is about ~2 nM (Swartz et al, 
1991). Since only extracellular KYNA can interact with neuronal excitatory receptors, 
normal KYNA concentrations are probably not sufficient to occupy a substantial portion 
of the receptor site(s). 
 
KYNA can penetrate the blood-brain barrier under physiological conditions via the 
large amino acid transporter that also transports L-kynurenine, the bio-precursor of 
KYNA, and tryptophan, the parent molecule of all the derivatives of the KYNA pathway 
(Fukui et al., 1991). Kynurenine pathway metabolites are actively accumulated by 
astrocytes and neurons in the brain. Uptake of these molecules by astrocytes is a sodium- 
13 
 independent process, which is far more efficient than the sodium-dependent neuronal 
uptake of these molecules (Speciale and Schwarcz, 1990). Kynurenine aminotransferase 
(KAT) is the enzyme that catalyzes the biosynthesis of KYNA from kynurenine. In contrast 
to the rat brain, the human brain contains two KAT isoforms - KAT I and KAT II, both of 
which have Km values for kynurenine in the low nanomolar range. Although, KAT II is 
considered to be predominantly present under physiological conditions, the existence of 
two distinct enzymes certainly raises questions concerning differential cellular 
localization, and the possible exclusive participation of only one KAT enzyme in 
processes related to KYNA dysfunction in the human brain (Okuno et al., 1991). 
 
Upon completing its function as an excitatory receptor antagonist, it is not clear 
whether KYNA is taken up by the neuronal cells, or exits the brain as it is. Moreover, the 
fate of KYNA following its emergence in the extracellular compartment in the brain is 
currently not well studied.  Sporadic reports have suggested the existence of specific 
KYNA-catabolizing enzymes (Takahashi et al., 1956; Horibata et al., 1961), however, so 
far no reproducible evidence has been reported either for the selective degradation or the 
successful reuptake of KYNA in the brain (Turski and Schwarcz, 1988). It has been 
suggested, though, that KYNA is removed from the brain by a probenecid-sensitive 
mechanism (Moroni et al., 1988). The question of KYNA removal from the brain needs 
more attention and the mechanisms need to be elaborated in greater detail in the future. 
 
KYNA induces the secretion of pro-inflammatory cytokines, such as interleukin-6  
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Figure 4. The activation of JAKs after cytokine stimulation results in the phosphorylation 
of STATs, which then dimerize and translocate to the nucleus to activate gene 
transcription. 
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 (IL-6), in human fetal astrocytic cultures, which in turn generates reactive astrocytes 
(Brown et al., 2010). Binding of IL-6 to its receptor, IL-6 receptor (IL-6R), activates the 
Janus kinase-signal transducer and activator of transcription (Jak-STAT) pathway (Figure 
4), which is an important pathway in gliogenesis (Brown, 2012). Autophosphorylation of 
Jak attracts STATs, including STAT3, phosphorylating STAT that dimerizes and functions 
as a transcription factor in the nucleus. Phosphorylated STAT3 binds to the promotor of 
Gfap gene and induces Gfap transcription. Gfap is a characteristic astrocyte gene, and 
increased Gfap expression is an indication of gliogenesis in development, and gliosis in 
an immune response (Meyer et al., 2011). 
 
The emerging picture of KYNA in developmental, molecular and cellular 
neuroscience is both increasingly complex and fascinating. The interplay between 
neurons and astrocytes is clearly central to an understanding of most KYNA-related 
mechanisms, so it appears prudent to focus future efforts on the careful investigation of 
neuron-glia relationships as they pertain to KYNA. 
 
Conclusion 
 
Numerous neuropsychiatric disorders including schizophrenia and autism 
spectrum disorders have been hypothesized to have a developmental origin where 
formation of the cortical circuitry is hampered during growth (Lewis et al., 2002; Haber et 
al., 2010; Money et al., 2013, Selemon and Zecevic, 2015). Such malformations in the  
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cortical circuitry can occur by modifications in the proliferation and differentiation of 
cortical RGCs that can give rise to both cortical neurons and glial cells (Fatemi et al., 
2002; Mo et a;., 2007; Howard et al., 2008; Endele et al., 2010). Previous studies in 
rodents and recent investigations in human neural precursor cells have described 
glutamate-mediated effects on proliferation and differentiation of neural precursors 
(LoTurco et al., 1991; Haydar et al., 2000; Suzuki et al., 2006). However, there is a lack 
of knowledge regarding the distribution, subunit composition, and role of NMDARs in 
human corticogenesis. We propose to explore the role of NMDARs in proliferation and 
differentiation of dorsal RGCs in human fetal brains at midgestation (~20 gw), which is a 
period of intense neurogenesis and synapse formation in the human cerebral cortex. 
 
Specifically, we first examined the spatial and temporal expression of the major 
NMDAR subunits (NR1, NR2A and NR2B) from 10 gw to 24 gw along various transitory 
layers (zones) of the cerebral wall in the human fetal cortex using qPCR, Western blotting, 
in situ hybridization, and immunohistochemistry.  
 
Secondly, we examined the role of NMDARs by blocking these receptors in vitro.  
We established mixed human cortical cultures and enriched human RGCs (CD15+) at 
midgestation (16-19 gw) using magnetic activated cell sorting (MACS). This in vitro 
system allowed us to use the NMDAR-specific antagonist D-APV, and an endogenous 
excitatory receptor antagonist KYNA, which possesses a high binding affinity for the NR1  
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 subunit of NMDARs. Using the human fetal RGC cultures, we examined the role of 
NMDARs on proliferation, specification and differentiation of human cortical progenitors 
by employing cell survival assay, qPCR, Western blotting, and immunostaining.  
 
Next, to determine if IL-6 is the cytokine released upon KYNA treatment in human 
fetal mixed cell cultures, we examined the levels of secreted IL-6 using sandwich ELISA. 
We further explored the activation of the Jak-STAT pathway by Western blotting for 
pSTAT3. In this aim we determined the levels of IL-6, and hypothesized that increasing 
concentrations of KYNA will increase reactive astrocyte population, elevate IL-6 
production and activate the Jak-STAT cell signaling pathway necessary for the astrocytic 
Gfap gene expression. The experiments in this aim will determine if NMDARs influence 
human neural progenitors through the Jak-STAT pathway. 
 
A thorough examination of significant molecules, like NMDARs, whose expression 
is spatially and temporally regulated during cortical development, is required to study the 
underlying causes for most of the complex brain disorders. The proposed studies, 
focused on human cerebral cortex development at midgestation will enable us to 
understand the role of NMDARs in proliferation, specification and differentiation of human 
cortical progenitors. The results obtained from these studies will give a better insight into 
the cortical development in humans, and in the future facilitate detection of drug targets 
and suggest novel therapeutic intervention for neuropsychiatric diseases. 
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Abstract  
N-methyl D-aspartate receptors (NMDARs), a subtype of glutamate receptor, have 
important functional roles in cellular activity and neuronal development. They are well-
studied in rodent and adult human brains, but limited information is available about their 
distribution in the human fetal cerebral cortex. Here we show that three NMDAR subunits, 
NR1, NR2A, and NR2B, are expressed in the human cerebral cortex during the second 
trimester of gestation, a period of intense neurogenesis and synaptogenesis. With 
increasing fetal age, expression of the NMDAR-encoding genes Grin1 (NR1) and Grin2a 
(NR2A) increased while Grin2b (NR2B) expression decreased. The protein levels of all 
three subunits paralleled the changes in gene expression. On cryosections, all three 
subunits were expressed in proliferative ventricular and subventricular zones, in radial 
glia, and in intermediate progenitor cells, consistent with their role in the proliferation of 
cortical progenitor cells and in the determination of their respective fates. The detection 
of NR1, NR2A, and NR2B in both glutamatergic and GABAergic neurons of the cortical 
plate suggests the involvement of NMDARs in the maturation of human cortical neurons 
and in early synapse formation. Our results and previous studies in rodents suggest that 
NMDAR expression in the developing human brain is evolutionarily conserved. 
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 Introduction 
N-methyl D-aspartate receptors (NMDARs) are ligand- and voltage-gated 
ionotropic glutamate receptors that play critical roles in synaptic plasticity, development, 
learning, and memory. Impairments in their function underlie the pathophysiology of 
several neurological diseases, including schizophrenia, autism spectrum disorder, and 
epilepsy (Malenka and Nicoll 1993; Naegele 2009; Endele et al. 2010; Wang et al. 2012, 
Sanz-Clemente et al. 2013, Cohen et al. 2015). In the developing brain, functional 
NMDARs are present even before synapses are established, to allow the influx of calcium 
(Ca2+) necessary for cellular activities such as signal transduction, gene transcription, 
and neuronal maturation (Pearce et al. 1987; Ben-Ari et al. 1988; Brewer and Cotman 
1989; reviewed in Spitzer 2006; Jansson and Akerman 2014). Physiologically relevant 
interactions between corticogenesis and NMDAR function have been demonstrated in 
several studies (LoTurco et al. 1991, 1995; Haydar et al. 2000). The early expression of 
NMDARs in the ventricular and subventricular zones (VZ/SVZ) is a prerequisite for the 
proliferation of neural stem cells, their differentiation into neurons and glia, and their 
proper migration through NMDAR-mediated Ca2+ transients (Rakic and Komuro 1995; 
Weissman et al. 2004; Manent et al. 2005; Toriumi et al. 2012).  
 
NMDARs are composed of four subunits, two NR1 and two NR2 or NR3 subunits, 
with NR1 being the obligatory subunit (Cull-Candy et al. 2001). In the developing rodent, 
NMDAR subunits undergo major changes in their expression levels, reflecting the specific  
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 physiological function of each receptor isoform in cell proliferation, synaptogenesis, and 
activity-dependent remodeling (Kleinschmidt et al. 1987, Bear et al. 1987; Constantine-
Paton et al. 1990; Monyer et al. 1994; Dumas 2005; Sanz-Clemente et al. 2013). 
Additional studies in rodents have shown age-related shifts in the expression levels of the 
NMDAR subunits, with the expression of NR2A increasing and that of NR2B decreasing 
with age (Barria and Malinow 2002; Rodenas-Ruano et al. 2012; Sanz-Clemente et al. 
2013). This shift has functional significance with respect to development of the cortical 
circuitry and cortical function (Dumas 2005).  
 
To better understand the functional role of NMDARs in human corticogenesis, it is 
essential to first study their expression pattern in the developing cerebral cortex. NMDARs 
distribution in the human fetal cortex has been explored in much less detail than in animal 
models. In humans, NMDARs distribution has been examined in late gestational and 
neonatal ages and in the adult brain (Conti et al. 1999; Law et al. 2003; Suzuki et al, 2006; 
Henson et al. 2008, Jantzie et al. 2015). The focus of the present study was the first half 
of gestation (10–24 gw), as in the human fetal cortex this is a critical period for 
neurogenesis, migration, and the beginning of synaptogenesis (Kostovic and Rakic 1990; 
Zecevic 1998; Rakic 2009; Marin-Padilla 1998; Zecevic et al. 1999; Meyer et al. 2000; 
Bayatti et al. 2008; Clowry et al. 2010; Malik et al., 2013). Using different methods, we 
demonstrated that NMDARs subunits are expressed by cortical progenitor cells and by 
young neurons. This cell-type specific distribution suggests roles for NMDARs in the 
proliferation and fate determination of cortical progenitor cells, and in maturation and  
32 
synaptogenesis of young cortical neurons during human corticogenesis. 
 
Material and Methods 
 
Human fetal brain tissue 
Human brain tissue (n = 11) from fetuses aged 10–24 gestational weeks (gw) 
(Table 1) and free of any developmental abnormalities was obtained from the Tissue 
Repository of The Albert Einstein College of Medicine (Bronx, NY) and the Human 
Developmental Biology Resource (http://hdbr.org), Newcastle upon Tyne, England. The 
tissues were handled according to the requirements and regulations of Institutional Ethics 
Committees. The age of the tissues was determined based on crown-rump length, 
number of weeks after donor ovulation, and anatomical landmarks. The tissues were 
transported on ice in Hank’s balanced salt solution (HBSS; Life Technologies, Grand 
Island, NY, USA) from the aforementioned brain repositories to our labortatory. Blocks of 
tissue cut in a coronal plane at the level of the thalamus were fixed, and cryopreserved, 
for in situ hybridization and immunohistochemistry. In addition small samples (1cm2) of 
unfixed tissue were taken from the whole width of dorsal and medial telencephalic wall 
for Western blot and qPCR. Whenever possible we used multiple methods on the same 
case, but not all the fetal ages or regions were available for every method used in this 
study. This is specified in Table 1 and in the Results.  
 
Immunohistochemistry  
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 Table 1 Description of human fetal tissue and methods used.  
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Case 
number 
Gestational 
Week 
Method Used 
1 10 In situ hybridization (ISH) 
2 15 qPCR, Western blot 
3 16 Immunohistochemistry, ISH 
4 17 qPCR, Western blot, Immunohistochemistry, ISH 
5 17 qPCR, Western blot, Immunohistochemistry, ISH 
6 18 qPCR, Western blot, Immunohistochemistry 
7 19 qPCR, Western blot, Immunocytochemistry, ISH 
8 21 qPCR, Western blot, Immunocytochemistry, ISH 
9 22 qPCR, Western blot, Immunocytochemistry, ISH 
10 23 qPCR, Western blot, Immunocytochemistry, ISH 
11 24 qPCR, Western blot, Immunocytochemistry, ISH 
Cryopreserved coronal sections (22 μm)  of the mid-gestational human fetal brain 
(Table 1)  were dried at 37°C for 3 h and then incubated in citrate buffer (pH 9.0) at 80°C 
for 7 min for antigen retrieval, placed in a humidifying chamber, and washed with 
phosphate-buffered saline containing 0.01% Triton X-100 (PBS-T). Unspecific antibody 
binding was inhibited by incubating the sections in a blocking solution consisting of 10% 
normal goat serum in PBS-T (NGS-PBS-T) for 1 h at room temperature (RT). Primary 
antibodies (Table 2) were diluted in 1% NGS-PBS-T. The sections were treated with 
primary antibody diluted in blocking solution, and incubated at 4°C overnight. After three 
5-min washes with PBS, the sections were incubated at RT for 2 h with flourophore-
conjugated secondary antibodies diluted in PBS. After a second PBS washing step (3 × 
5 min each), the sections were incubated with the nuclear stain bisbenzimide (BB) for 1 
min at RT.  
 
Immunohistochemistry image analysis 
Immunolabeled sections were visualized using an Axioscope microscope (Zeiss, 
Germany) with Axiovision software and photographed using a digital camera. Twelve 
images were taken from predesignated adjacent optical fields in dorsal or dorso-medial 
portion of the telencephalic wall and from three different human samples per experimental 
group for cell counting. Optical sectioning (in steps of 1 μm thickness) were taken from 
20 μm cryosections to clearly observe the co-localization of the immunostaining. The 
images were compressed in the Z-plane to obtain maximum intensity projection images, 
and assembled in Adobe Photoshop (v. 7.0), with consistent quality adjustments for  
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 Table 2 Antibodies used for immunocytochemistry and Western blotting.  
Primary Antibody Cell Type Identified Species Dilution Company 
NR1 - mouse 1:200 NeuroMab 
NR2A - mouse 1:200 NeuroMab 
NR2B - mouse 1:200 NeuroMab 
Hopx Basal RGC Rabbit 1:200 Santa Cruz 
Ki67 Proliferating Cells rabbit 1:500 Abcam 
Pax6 RGC rabbit 1:250 Abcam 
Tbr2 Intermediate Progenitor rabbit 1:200 Abcam 
Nkx2.1 Interneuron Progenitor rabbit 1:200 Abcam 
βIII tubulin Neuron rabbit 1:5000 Sigma-Aldrich 
Tbr1 Glutamatergic Neuron rabbit 1:200 Proteintech 
GABA Interneuron rabbit 1:500 Sigma-Aldrich 
CalR Interneuron rabbit 1:500 Swant 
GAPDH Housekeeping mouse 1:5000 Millipore 
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contrast, brightness and color balance. Immunolabeled cells were counted in separate 
channels corresponding to each antibody. Cells that showed immunoreaction for both 
applied antibodies were quantified as a percentage of the total cell number in the optical  
fields labeled with the nuclear dye bisbensimide (BB). One-way ANOVA followed by a 
Bonferroni post hoc test was used for comparisons of the three groups categorized by 
age. 
 
Western blot  
Human cortical tissue (Table 1),  was homogenized in hypotonic phosphate buffer 
containing protease and phosphatase inhibitors (PMSF (1 mM), NaF (5 mM), Na-
orthovanadate (1 mM), PIC (1 mM; Thermo Scientific)), freeze-thawed, and centrifuged 
at 600 × g. The supernatant was mixed with RIPA buffer (150 mM NaCl, 1.0% Triton X-
100, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease and 
phosphatase inhibitors (same as above), freeze-thawed, and centrifuged at 13000 × g for 
15 min and the resulting supernatant was collected. To obtain membrane proteins the 
pellet was re-suspended in RIPA buffer containing protease and phosphatase inhibitors, 
freeze-thawed, and then centrifuged at 10000 × g for 15 min and the resulting supernatant 
was used for experimental analysis. The protein concentration of the samples was 
determined using the BCA protein assay kit (Thermo Fisher Scientific).  Polyacrylamide 
gels (4–12%; Bio-Rad) were then used to separate the proteins based on their molecular 
mass at 110 Volts for 90 min. Samples were run, on three separate gels, to obtain results 
in triplicates. The separated proteins were electro-transferred onto a polyvinylidene  
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 fluoride membrane at 100 Volts for 60 min. A Ponceau stain on every blot, and a 
Coomassie stain for every gel was performed to confirm complete transfer of separated 
proteins. The membrane (blot) was blocked with 5% milk in TBS-T (1.0% Tween-20, PBS, 
0.1% Triton X-100, distilled water; pH 7.4) and then incubated overnight at 4°C with 
primary antibodies (Table 2) diluted in blocking solution (0.1 M Tris, 2% non-fat  dry milk, 
0.15 M NaCl, 0.01% Na-azide, pH 7.4) against the proteins of interest. After three washes, 
the blot was incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Millipore) for 2 h at RT. After three washes, blots were incubated with 
SuperSignal West Dura Extended Duration Substrate (Thermo Scientific), and imaged on 
ChemiDoc MP (Bio-Rad) digital imaging system. The loading control for each blot was 
GAPDH (primary antibody dilution 1:5000). The density of each band was determined in 
Adobe Photoshop (v.7.0) using histogram analysis. The values obtained for each band 
were divided by the value of the corresponding GAPDH band. The averaged values 
obtained from groups 18-21 gw and 22-24 gw were normalized to the group 15-17 gw to 
overcome individual differences between tissue samples.   
 
RT-PCR and qPCR 
Human cerebral cortex tissue (15–24 gw, Table 1), dissected as described above, 
was used for RNA isolation and qPCR analysis. The tissue was treated with ice-cold 
TRIZOL® reagent (Invitrogen) for 10 min followed by mechanical homogenization. After 
the addition of chloroform (200 μl) to the homogenates, the tubes were vortexed and 
incubated for 15 min at 4°C. They were then centrifuged at 13000 × g for 15 min at 4°C.  
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Table 3 Primers used for qPCR. 
Genes Forward Primer Sequence Reverse Primer Sequence 
Grin1 
5`-CCA GTC AAG AAG GTG 
ATC TGC AC-3` 
5`-TTC ATG GTC CGT GCC 
AGC TTG A-3` 
Grin2a 
5`-CTC TCC TTG GAA GAG 
GCA GAT C-3` 
5`-TGG CTG CTC ATC ACC 
TCG TTC T-3` 
Grin2b 
5`-TTC CAC TGG CTA TGG 
CAT TGC C-3` 
5`-GAC AAA TGC CAG TGA 
GCC AGA G-3` 
Gapdh 
5`-ACC ACC ATG GAG AAG 
GC-3` 
5`-GGC ATG GAC TGT GGT 
CAT GA-3` 
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 The upper transparent phase was collected in sterile tubes and incubated with 
isopropanol (500 μl/ tube) for 20 min at RT, followed by centrifugation at 13000 × g for 
15 min at 4°C. The pellets were incubated with 75% ethanol at 4°C and then centrifuged 
at 13000 × g for 15 min to pellet the RNA. The air-dried RNA was dissolved in 5% 
RNase Out solution. RNA concentrations were determined using NanoDrop technology 
(260/280 ratio obtained was between 1.93 and 2.0). cDNAs (40 μl) were synthesized 
from 1-μg RNA samples using reverse transcriptase-PCR and the first-strand synthesis 
SuperScript III kit (Invitrogen). cDNA concentrations were determined using NanoDrop 
technology with 260/280 ratios between 1.79 and 1.81. We pooled aliquots of all the 
cDNA samples to generate a standard curve (samples run in triplicates on the same 
plate) with the log (DNA copy#) plotted on the Y-axis and the cycle of threshold (Ct) 
value plotted on the X-axis, to determine the efficiency of the qPCR protocol. The slope 
determined from the standard curve was used to calculate the efficiency of the qPCR 
process. The SYBR Green (Applied Biosystems, Cheshire, UK) protocol was applied to 
the cDNA samples to analyze the mRNA expression levels of the genes of interest. 
Gene specific primers are presented in Table 3.. The qPCR protocol involved a heating 
step at 95°C for 2 min followed by 40 cycles at 95°C for 15 s, 55°C for 15 s, and 68°C 
for 20 s. The cycle of threshold (Ct) values of GAPDH were subtracted from those of the 
genes of interest to obtain a ΔCt value. The ΔCt values were averaged for each age 
group. The ΔCt values of groups 18-21 gw and 22-24 gw  were then subtracted from the 
value of the age group 15-17 gw to obtain the ΔΔCt value. The formula 2-ΔΔCt was 
used to determine the fold change in mRNA expression level in group 18-21 gw and 22- 
40 
24 gw relative to the group 15-17 gw, which was assigned an arbitrary value of 1. This 
normalization aids in dealing with the variations between the qualities of the original 
tissues used to generate the cDNA samples. 
 
In situ hybridization 
The genes Grin1, Grin2a, and Grin2b encode the NMDAR subunits NR1, NR2A, 
and NR2B, respectively. Plasmids containing the Grin1, Grin2a, and Grin2b coding 
sequences (pEYFP-NR1a, pEGFP-NR2A, and pEGFP-NR2B, respectively) were used 
for probe synthesis (Luo et al., 2002). The plasmids pEGFP-NR1a (Addgene plasmid 
#17926), pEGFP-NR2A (Addgene plasmid #17924), and pEGFP-NR2B (Addgene 
plasmid #17925) were gifts from Stefano Vicini (Department of Pharmacology & 
Physiology, Georgetown University Medical Center, Washington DC). Riboprobes were 
generated by in vitro transcription of a PCR fragment (primer sequences in Table 4) 
containing part of the gene sequence flanked by T3/SP6 promoter sequences, using 
digoxigenin (DIG)-UTP (Roche) as the label. In situ hybridization was performed as 
previously described (Radonjic et al., 2014). Briefly, cryosections (20 μm)  were dried at 
RT for 2 h, fixed for 10 min with 4% paraformaldehyde in PBS, washed twice in diethyl 
pyrocarbonate (DEPC)-treated PBS, and incubated overnight at 68°C in hybridization 
buffer containing 1× DEPC-treated salts [200 mM NaCl, 5 mM EDTA, 10 mM Tris, pH 7.5, 
5 mM NaH2PO4·2H2O, 5 mM Na2HPO4; Sigma-Aldrich), 50% deionized formamide 
(Roche), 0.1 mg RNase-free yeast tRNA (Invitrogen, Carlsbad, CA, USA)/mL, 1× 
Denhardts (RNase/DNase free; Invitrogen), and 10% dextran sulfate (Sigma-Aldrich)]  
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 Table 4 Primers used for riboprobe synthesis. 
Gene Forward Primer Sequence Reverse Primer Sequence 
Grin1 with 
SP6 
5`-CCG ATT TAG GTG ACA CTA 
TAG GAC TGA-3` 
- 
Grin1 with 
T3 
- 
5`-CCG GCA ATT AAC CCT 
CAC TAA AGG CGT AGA TAA 
ACT TGT CCG AGG G-3` 
Grin2a with 
T3 
5`-GCA ATT AAC CCT CAC TAA 
AGG TCT CCC TGG TGA CCA 
CTA TCT T-3` 
- 
Grin2a with 
SP6 
- 
5`-ATT TAG GTG ACA CTA 
TAG TGA TAG ACC ACT TCA 
CCG ATC A-3` 
Grin2b with 
T3 
5`- GCA ATT AAC CCT CAC TAA 
AGG AGT TCA ACC AGA GGG 
GTG TGA A-3` 
- 
Grin2b with 
SP6 
- 
5`-ATT TAG GTG ACA CTA 
TAG GGT GGG TTG TCA 
CAG TCG TAG-3` 
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and 100–500 ng DIG-labeled RNA probe/ml. After hybridization, the sections were 
washed three times at 65°C in a solution containing 50% formamide, 1× saline-sodium 
citrate (Invitrogen), and 0.1% Tween 20 (Sigma-Aldrich) and three times at RT in 1× 
MABT (20 mM maleic acid, 30 mM NaCl, 0.1% Tween 20; Sigma-Aldrich). They were 
then incubated for 1 h at RT in a solution containing 2% blocking reagent (11096176001; 
Roche) and 10% heat-inactivated sheep serum in MABT, followed by an overnight 
incubation at 4 oC in alkaline-phosphatase-conjugated anti-DIG antibody (1:1500; Roche 
Applied Science, catalogue no. 11093274910 RRID:AB_514497). The specificity of the 
procedure was assessed with probes corresponding to the sense strands of Grin1, 
Grin2a, and Grin2b. The whole section pictures (4X magnification) that are part of Figure 
2 were done on the Aperio Versa (LeicaBiosystems.com), following manufactures 
instructions.  
 
Statistical analysis 
For all Western Blot and qPCR experiments, triplicate values were averaged to 
obtain a mean value for each brain. Three groups, each consisting of at least three brains, 
were established according to the gestational age: 15-17 gw, 18–21 gw, and 22–24 gw. 
The means obtained from each brain in a group were averaged to obtain a group mean. 
Variations were expressed as the mean ± standard error (SEM). One-way ANOVA 
followed by Bonferroni’s post-hoc test was used to evaluate statistical significance, 
defined as a p value <0.05.     
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 Results 
 
NMDARs are expressed in the human fetal cerebral cortex  
The quantitative expression of the genes encoding the major NMDAR subunits, 
NR1, NR2A, and NR2B, was assessed by qPCR and Western blot analysis in three age 
groups – 15-17 gw, 18-21 gw and 22-24 gw. Our results demonstrate that the expression 
of Grin1, gene encoding NR1 subunit, increases with age (p<0.05; Figure 5A). The same 
trend was observed in expression of the gene encoding the NR2A subunit, Grin2a (Figure 
5A). In contrast, expression of the NR2B gene, Grin2b, decreased with increasing age 
studied here (p<0.05; Figure 5A). To determine whether these changes in gene 
expression also occurred at the protein level, tissue lysates obtained from human fetal 
cerebral cortex of the same gestational ages were analyzed by Western blotting (Figure 
5B). Expression of NR1 protein between all three age groups was fairly uniform (Figure 
5B,C). We hypothesize that the discrepancy between the NR1 gene and protein 
expression is due to the high rate of Grin1 transcription accompanied by a high turnover 
rate of the NR1 transcript. At the same time, translation of the NR1 transcript is dependent 
on the cellular activity (reviewed in Paoletti et al., 2013). The expression of NR2A protein 
increased across the three age groups while that of NR2B decreased across the three 
age groups studied (Figure 5C) (p<0.05), congruent with  qPCR results. Although the 
relatively short developmental time span studied here does not allow firm conclusions 
about the timing of the developmental switch from NR2B to NR2A in human cerebral 
cortex, our results suggest that it begins during midgestation (22–24 gw).  
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 Figure 5. The three NMDAR subunits, NR1, NR2A, and NR2B, are expressed in human 
fetal brain at mid-gestation. (A) Expression of the genes Grin1 and Grin2a increases with 
age, while that of Grin2b decreases from the youngest group 15-17 gw to the oldest group 
22-24 gw (n=3 per age group; p<0.05). The mean values are plotted; the error bars 
represent ± the SEM. (B) Western blot of the NR1, NR2A, and NR2B subunits across all 
ages studied. GAPDH is the loading control. (C) Densitometric analysis confirms that NR1 
protein expression does not change with age, while NR2A and NR2B protein levels 
parallel the trend in the expression of their respective genes, with an age-dependent 
increase in NR2A and decrease in NR2B (n=3 per age group; p<0.05). The mean values 
are plotted; the error bars represent ± the SEM. 
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 Distribution of NMDAR mRNAs and proteins in the human cerebral wall  
The distribution of the NR1, NR2A, and NR2B transcripts were examined in sagittal 
(10gw) and coronal cryosections (Figure 6 A,B), while the NR1, NR2A, and NR2B 
proteins were examined on coronal cryosections (Figure 7 A,B) of fetal brains taken at 
the level of the thalamus (16- 24gw, Table 1). In situ hybridization experiments revealed 
that the mRNAs of all three subunits were distributed in the developing cortex as early as 
10 gw (Figure 6A) and were also present during midgestation, at 17-22 gw (Figure 6B). 
High levels of expression were seen in the proliferative VZ/SVZ compartments, in the 
transient migratory zones, the intermediate zone (IZ) and the subplate (SP), and in the 
neuron-rich cortical plate (CP). High magnification images of the VZ and CP (Figure 6A,B) 
at 10 and 22 gw indicates that the transcripts of the NMDAR subunits, exhibiting both a 
punctate and diffuse pattern of expression, are present in almost every cell. These 
findings suggest that both cortical progenitors and neurons actively transcribe the 
NMDAR subunit genes during neurogenesis. Immunolabeling with NMDAR subunit-
specific antibodies revealed the presence of NR1, NR2A, and NR2B in the cell bodies 
and processes across the telencephalic wall at all examined ages, as shown in 
representative samples of 17 gw (Figure 7A), and 22 gw (Figure 7B). The 
immunoreactivity has a transverse pattern along the VZ and SVZ suggestive of the 
expression of NMDAR subunits along efferent and afferent fibers/processes, as 
expression of NMDARs was reported at both the pre-synaptic and post-synaptic sites 
(Herkert et al., 1998). In the SP and CP, the immunoreactivity for the NMDAR subunits 
exhibits a radial pattern that corresponds to the radial glial fibers and organization of cell  
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Figure 6. Distributions of NR1, NR2A, and NR2B transcripts in the telencephalic wall. In 
situ hybridization reveals the presence of Grin1, Grin2a, and Grin2b mRNAs in the 
proliferative ventricular zone (VZ) and neuron-rich cortical plate (CP) as early as (A) 10 
gw (sagittal section) and (B) at 22 gw (coronal section). Higher magnifications of the CP 
and VZ are shown in the insets. (C) Sense (control) probes for Grin1, Grin2a, and Grin2b 
shown for 10 gw. D-dorsal, M-medial, R-rostral. The whole sections images are captured 
by Aperio Versa (LeicaBiosystems.com), at 4X. 
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Figure 7. Immunohistochemistry of NR1, NR2A, and NR2B (green) along the various 
zones of the telencephalic wall of a representative case at 17 gw (A) and 22 gw (B). 
Greater immunolabeling intensity is seen for NR2A at 22 gw compared to 17gw, whereas 
the opposite is seen for NR2B subunit.(C) NR1 (green) expression on proliferative 
progenitors (Ki67+; red) in the VZ and (D) on basal radial glia (Hopx+; red) in the SVZ. 
Arrows point to double-labelled cells. Cell nuclei stained blue with bisbenzimide (BB).  
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bodies in the CP. The highest levels of these proteins were detected in the same regions  
containing the highest levels of their respective transcripts, namely, in the VZ/SVZ, and 
CP. Proliferating cells (Ki67+ cells) in the VZ expressed the NR1 subunit (Figure 7C) as 
well as the NR2A and NR2B subunits. Moreover, primate-specific basal radial glial cells 
(RGCs), recognized by their expression of the transcription factor Hopx (Pollen et al. 
2015; Li et al. 2015; Thomsen et al. 2016), also expressed NR1 (Figure 7D) as well as 
NR2A and NR2B.  
 
NMDAR expression by cortical progenitor subtypes 
The abundant expression of NR1, NR2A, and NR2B mRNA and protein in the 
proliferative and neuron-rich zones of the fetal brain suggested that the three subunits 
would be expressed by multipotent cortical progenitors, RGCs, intermediate progenitors, 
and cortical neurons. To detect expression in particular cell types at these sites, coronal 
cryosections of fetal forebrains at different gestational ages were evaluated using double-
labeling immunohistochemistry to co-localize cell-type specific markers and each of the 
NMDAR subunits (Figure 8A; Table 2). Quantification of the double-labeled cells showed 
that the vast majority of RGCs labeled with the Pax6 antibody expressed all three NMDAR 
subunits. The NR1 subunit was present in 90–95% of the RGCs in all age groups studied. 
In RGCs of the youngest age group (16–18 gw, n= 3), the expression of NR2B was higher 
than that of NR2A (85% vs. 75%), whereas in subsequent gestational weeks (18–21 gw, 
n=3) expression of these two subunits was nearly equal. As development proceeded to 
22–24 gw (n=3), however, a higher percentage of RGCs expressed NR2A (88%) than  
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Figure 8. Expression of NMDAR subunits on cortical progenitors. (A) Representative 
images of coronal cryosections at 17 gw. Double immunolabeling experiments with 
antibodies against the NR1, NR2A, and NR2B NMDAR subunits (green) and the 
progenitor subtypes (red) Pax6 (RGCs), Tbr2 (intermediate progenitors) and Nkx2.1 
(interneuron progenitors) in the proliferative VZ/SVZ. Cell nuclei stained blue with BB. 
Boxed areas are presented on higher magnification in the inset.  (B) Quantification of the 
percentage of Pax6+, Tbr2+, and Nkx2.1+ progenitors expressing the three NMDAR 
subunits in the three age groups (n=3 per age group; p<0.05); The mean values are 
plotted; the error bars represent ± the SEM. 
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NR2B (64%) (Figure 8B). Thus, during an 8-week period in the second trimester of 
gestation the expression of NR2B in RGCs decreased while that of NR2A increased. 
Quantification of intermediate progenitor cells labeled with Tbr2 and a subtype of 
interneuron progenitors labeled with Nkx2.1 that express NR1 showed a similar age-
dependent increase (Figure 8B). Specifically, NR1 was expressed in 25% of Tbr2+ cells 
and 35% of Nkx2.1+ cells, with expression during the subsequent weeks of gestation 
increasing to >40% in both subtypes. These results suggested an age-dependent 
increase in NR1 and NR2A expression in intermediate progenitors (Tbr2+) and Nkx2.1+ 
interneuron progenitors. However, in contrast to RGCs, NR2B expression in the oldest 
group did not change in Nkx2.1+ cells and it increased only slightly in Tbr2+ progenitors 
(Figure 8B).  
 
Glutamatergic and GABAergic neurons express NMDARs 
To determine the expression levels of the NMDAR subunits across post-mitotic 
neurons in their final positions in the CP, immunolabeling experiments were carried out 
similar to those described above, but with antibodies specific to the different neuronal 
subtypes (Figure 9A; Table 2). Double-labeling immunohistochemistry of tissues between 
16 and 24 gw revealed that all embryonic neurons labeled with a pan-neuronal marker 
βIII tubulin expressed NR1, the obligatory NMDAR subunit (Figure 9B). This is in 
agreement with results showing that mature neurons are electrically active and express 
NMDARs (Lu et al. 2001; Cull-Candy et al. 2001, 2004; Henson et al. 2008). The 
expression of NR2B and NR2A in cortical neurons (βIII tubulin+ cells), however, changed  
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Figure 9. Expression of NMDAR subunits on cortical neurons. (A) Representative images 
at 17 gw. Double immunolabeling experiments with antibodies against the NR1, NR2A, 
and NR2B NMDAR subunits (green) and the neuronal subtypes (red) βIII tubulin 
(neurons), Tbr1 (glutamatergic), GABA (interneurons), and calretinin (interneuron 
subtype) in the cortical plate (CP) and the transient intermediate zone (IZ). Cell nuclei 
stained blue with BB. Arrows point to cells presented on higher magnification in the inset.  
(B) Quantification of the percentage of βIII tubulin+ neurons, Tbr1+ glutamatergic neurons, 
and GABA+ interneurons expressing the three NMDAR subunits in the three age groups 
studied (n=3 per age group; p<0.05). The mean values are plotted; the error bars 
represent ± the SEM. 
51 
over the 8-week developmental period studied. In the youngest group (16–18 gw, 
n=3), 92% of all neurons expressed NR2B whereas only 70% expressed NR2A. In the 
next studied stage, 18–21 gw brains (n=3), almost equal number of neurons expressed 
NR2B (85%) and NR2A (83%). In the oldest group of brains studied (22–24 gw, n=3), the 
expression of NR2A (91%) was higher than that of NR2B (84%) (Figure 9B). These semi-
quantitative results on the neuronal expression of the three subunits were comparable to 
those obtained with the cortical RGC progenitors, in which an increase in the expression 
of NR2A vs. NR2B was demonstrated. 
 
We then quantified expression of the NMDAR subunits by Tbr1+ glutamatergic neurons 
and GABA+ interneurons. In all three age groups studied, nearly all Tbr1+ cells (98%) 
expressed the obligatory NR1 subunit, whereas with increasing age, expression of the 
NR2B subunit by these cells decreased (90% to 83%; p<0.05) and that of the NR2A 
subunit increased (67% to 94%; p<0.05) (Figure 5B). Similarly, a majority of GABAergic 
cortical interneurons (92%),  expressed NR1 across all studied ages (16–24 gw).and  with 
increasing age, the number of NR2B-positive GABAergic cells decreased (83% to 79%; 
p<0.05) whereas the number of NR2A-positive cells increased (77% to 83%; p<0.05) 
(Figure 9B).  
 
These results revealed that all three subunits are expressed on glutamatergic and 
GABAergic neuronal subpopulations during the second trimester of human gestation, with 
a specific temporal distribution pattern determined for each one.  
52 
 Discussion  
 
This study demonstrated the expression of the major NMDAR subunits, NR1, 
NR2A, and NR2B, at both the mRNA and protein levels, in the human fetal cerebral cortex 
during the second trimester of gestation. It also showed that between 16 and 24 gw the 
subunits are expressed by specific cell types within the different layers of the 
telencephalic wall. These findings extend previous studies on human brain tissue 
obtained at older stages of fetal development and from the adult brain (Conti et al. 1999; 
Law et al. 2003; Suzuki et al, 2006; Henson et al. 2008, Jantzie et al. 2015). The early 
distribution of NR1, NR2A, and NR2B in the human cerebral cortex suggests their early 
and distinct roles in cortical progenitor proliferation and specification, and in the 
maturation and synaptogenesis of excitatory and inhibitory neurons in this brain region.  
 
NMDAR in cortical progenitor cells  
From 16 gw onwards, all three NMDAR subunits were expressed on RGCs, the 
multipotent cortical progenitors in the VZ/SVZ. Both proliferating (Ki67+) RGCs in the VZ 
and basal RGCs (Hopx+) in the SVZ expressed NR1, NR2A, and NR2B. The three 
subunits were also expressed, although less abundantly, by cells in the next stage of 
RGC specification, that is, intermediate (Tbr2+) and interneuron (Nkx2.1+) progenitors. 
This suggests that glutamate is more important in the proliferation of RGCs than in their 
specification into a particular intermediate progenitor cell type. The different age-related 
patterning of expression of NR2B in RGC, intermediate and interneuron progenitors  
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suggests a role of this subunit in the specification of cortical progenitors, while NR2A 
containing NMDARs might be important for further neuronal differentiation. However, we 
cannot exclude the possibility that technical difficulties related to simultaneous labeling of 
nuclear transcription factors (Tbr2, Nkx2.1), and membrane receptor proteins (such as 
NMDARs) affect the efficiency of the method. 
 
The major excitatory neurotransmitter glutamate acts non-synaptically as a trophic 
factor during the early stages of development (Balasz 1996; Haydar et al. 2000). In 
rodents, glutamate increases progenitor proliferation in the VZ and promotes neuronal 
differentiation in the SVZ by modulating the length of the cell cycle (LoTurco et al. 1991; 
Takahashi et al. 1996; Haydar et al. 2000). These effects of glutamate on cortical 
progenitors are exerted through both AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate) receptors and NMDARs (LoTurco et al. 1995; Jansson et al. 1996; Behar et 
al. 1999). The early expression of NMDARs influences both the proliferation and 
differentiation of neural stem cells and the correct migration of newly generated neurons 
(Rakic and Komuro 1995; Manent et al. 2005; Toriumi et al. 2012). Experiments in which 
the activity of the NMDAR subunits was pharmacologically blocked or their expression 
genetically knocked out confirmed the significance of these receptors in cortical 
development. In rodents, pharmacological inhibition of the three NMDAR subunits during 
development was shown to induce severe neurodegeneration followed by death (Reiprich 
et al. 2005; Ikonomidou et al. 1999), whereas homozygous knockouts of NR1 and NR2B 
are neonatally lethal (Ikeda et al. 1992; Forrest et al. 1994; Kutsuwada et al. 1996;  
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 Sakimura et al. 1995). Other studies in rodents have shown that NMDARs play a crucial 
role in maintaining the stemness of RGCs in the adult dentate gyrus, by regulating the 
proliferation of these cells; NMDARs also participate in the establishment of hippocampal 
circuits (Bernabeu and Sharp 2000; Deisseroth et al. 2004; Nacher et al. 2006). In 
accordance with these observations, our recent in vitro study showed that antagonizing 
NMDARs on human fetal RGCs not only increases cell death but decreases progenitor 
specification and neurogenesis (Bagasrawala et al. in revision). These results provide 
strong evidence of the importance of NMDARs in the survival, proliferation, and 
differentiation of RGCs during human cortical development.  
 
NMDAR expression in cortical neurons 
All the βIII-tubulin-labeled neurons in the CP at mid-gestation (16–24 gw) 
expressed NR1, and a subpopulation of neurons expressed NR2B and NR2A. 
Specifically, both Tbr1+ glutamatergic and GABAergic neurons expressed all three 
NMDAR subunits during the second trimester of human gestation. NMDAR presence in 
neurons of the emerging CP suggests a role for this receptor in neuronal maturation and 
the establishment of the early synapses that appear in the human cortex at that time/stage 
(Zecevic 1998; Zecevic et al. 1999; Kostovic et al. 2002). Our previous 
electrophysiological studies, in which patch-clamp recordings were obtained from human 
fetal slice cultures, showed that glutamate acts through both AMPA receptors and 
NMDARs on Cajal-Retzius cells at mid-gestation (Lu et al. 2001). In another study, we 
demonstrated the presence of functional ionotropic glutamate receptors in human fetal  
55 
cortical neurons in acute brain slices (Moore et al. 2011).  
 
In the present work, we established that, in the oldest age group examined, the 
percentage of Tbr1+ neurons expressing NR2B and NR2A was slightly higher than the 
percentage of GABAergic cells expressing these subunits, compared to their respective 
percentages in the youngest age group. This finding suggests the functional differences 
or/and non-uniform maturation of cortical neurons at this developmental stage. The 
distribution of NMDARs in different subtypes of cortical neurons has clinical relevance, as 
the abnormal excitation of GABAergic interneurons due to NMDAR hypofunction results 
in cortical disinhibition and impairment of the synchronized activity of cortical projection 
neurons (Belforte et al. 2010; Nakazawa et al. 2012). In animal models, this disruption in 
cortical circuitry function leads to the development of behavioral deficits, such as 
anhedonia, disruption of the prepulse acoustic startle response, and anxiety, behaviors 
that closely resemble those observed in schizophrenia patients (Belforte et al. 2010). 
Furthermore, midgestation, when, as we determined here, all three NMDARs subunits 
are expressed by cortical neurons, is the period of upper cortical layer development, and 
the formation of the cortico-cortical connections necessary for establishing the higher 
cognitive functions that characterize humans (Rakic 1998; Hill and Walsh 2005). The 
disruption of cognitive processes is one of the major symptoms observed in complex 
neuro-developmental disorders, such as schizophrenia and autism spectrum disorder 
(Hill and Walsh 2005; Nakazawa et al. 2012).  
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 NMDAR expression on glia 
It is not surprising that the NMDAR subunits were detected on glial cells in the 
human fetal brain tissue. In the last two decades there have been several attempts to 
detect NMDAR subunits in astrocytes. The astrocytic protein marker GFAP was 
demonstrated on cells expressing the NR1 subunit mRNA in rat brain cortical slices (Aoki 
et al., in 1994). Other in situ hybridization studies in adult rat cerebellar Bergmann glial 
cells confirmed the presence of NR2C and NR2B mRNA transcripts (Akazawa et al., 
1994; Luque and Richards, 1995). However, functional NMDARs cannot be formed 
without the NR1 subunit. Even though NMDAR-mediated calcium currents are observed 
in astrocytes (Palygin et al., 2010; Lalo et al., 2011), the role of NMDARs in astrocytes 
still remains controversial. NMDARs play an important role in many CNS pathologies such 
as multiple sclerosis (Matute, 2011), as well as certain neurodegenerative diseases, such 
as Huntington’s (Hardingham, 2009) by maintaining the excitability of neuronal circuits. 
The mechanisms underlying NMDAR-dependent apoptosis are uncertain, but are likely 
to involve the release of apoptotic factors such as cytochrome c from mitochondria and 
the activation of stress-induced pathways such as that of p38 MAP kinase or c-Jun N-
terminal kinase (Hardingham and Badding, 2003). 
 
The expression of NMDAR subunits on oligodendrocytes was unexpected since 
not many studies have reported the expression or function of NMDARs in 
oligodendrocyte-specific activities. Oligodendrocytes were thought to express 
predominantly non-NMDA glutamate ionotropic receptors, and initial reports also  
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disclosed that oligodendrocytes do not respond to NMDA (Cull-Candy and Wyllie, 1991). 
However, in 1996, Yoshioka and colleagues showed, for the first time, that NMDARs are 
expressed in oligodendrocytes, using RT-PCR and Southern blotting in the rat 
oligodendroglial lineage CG-4. Furthermore, the expression of NR1, NR2A-D and NR3A 
has been demonstrated in the oligodendrocytes of the optic nerve (Salter and Fern in 
2005). As for the myelination process, several studies have shown the importance of 
NMDARs in immature oligodendrocytes, since even small calcium signals can influence 
the stabilization/retraction of the myelinating projections from oligodendrocytes due to the 
small intracellular space (Salter and Fern, 2005; Karadottir et al., 2005; Wong, 2006). 
 
Few studies have characterized the functional expression of ionotropic glutamate 
receptors in microglial cells. The expression of functional NMDARs in microglia in normal 
brain has not been reported (Gottlieb and Matute, 1997). Similar to these observations, 
our results also suggest that microglia do not express NMDARs in human cortical tissue 
at midgestation. However, NMDA injection into the somatosensory cortex of newborn rats 
triggers transient microglial activation (Acarin et al., 1996). Whether NMDAR controls 
microglial activation directly or indirectly remains to be determined. Therefore, additional 
studies are necessary to characterize the existence of functional ionotropic glutamate 
receptors in the resident and activated microglia of slices, which could respond to 
glutamate release during synaptic activity or damage. 
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 NMDAR composition 
The obligatory NR1 subunit was expressed in almost all of the investigated cell 
types. This was not surprising since the importance of this subunit in rodents is well-
established. For example, the controlled ablation of NR1 during development was shown 
to disrupt the normal maturation of the cell circuitry in the hippocampus, resulting in a 
schizophrenia-like cognitive decline and behavioral deficits later in life (Rodenas-Ruano 
et al. 2012). Our finding of the age-dependent expression of subunits NR2A and NR2B in 
human fetal cortex is in line with the results of animal studies. Synaptic activity is one of 
the factors regulating NMDAR subunit expression (Sanz-Clemente et al. 2013). NR2B-
rich NMDARs are found in abundance on developing synapses, where they generate slow 
currents with shorter amplitudes but lasting twice as long compared to NR2A-mediated 
currents. This allows for a large influx of Ca2+ that promotes gene transcription and 
extends the period of membrane depolarization, which is crucial for generating a strong 
and stable synapse (Yasuda et al. 2011). At the beginning of cortical synaptogenesis, 
NR2B is needed for the formation of the synaptic connections essential for circuitry 
formation. Many of these synapses undergo pruning, a process that is dependent on 
environmental experiences, the nature of the stimulus, and age (Rakic et al. 1986; Dumas 
2005; Sanz-Clemente et al. 2013; reviewed in Paoletti et al. 2013). In the adult brain, the 
strong circuitry connections established by NMDARs mainly containing the NR2B subunit 
ensure memory formation through long-term potentiation (Sanz-Clemente et al. 2010). 
Experiments using antagonists of the NR2A and NR2B subunits in monkey prefrontal 
cortical slices (Wang et al. 2011) showed that NR2B-type activity on postsynaptic spines  
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participates in working memory and learning. Similar results were obtained in mice 
genetically modified to lack the NR2B subunit during their postnatal development (von 
Engelhardt et al. 2008). As corticogenesis in rodents proceeds into the second postnatal 
week, the NR2B subunits translocate to extrasynaptic sites and are replaced at the 
synapse by NR2A-rich NMDARs (Malenka and Nicoll 1999; Dumas 2005). These 
synapses generate the fast currents required for strong and transient synaptic 
connections in response to sensory stimuli (Nakagawa et al. 1996; Paupard et al. 1997; 
Malenka and Nicoll 1999; Malatesta et al. 2000). Thus, in rats reared in the dark without 
appropriate sensory input, the NR2B-NR2A switch in the visual cortex is impaired, but the 
impairment can be reversed by exposing the animals to light (Philpot et al. 2001). During 
activity-dependent synaptic plasticity, NR2B-rich NMDARs move into synaptic sites from 
their previous extrasynaptic location via lateral diffusion (Tovar and Westbrook 2002; 
Groc et al. 2006). The timing of the switch coincides with the development of associative 
learning abilities, indicating the significance of this process in modifying and tweaking 
neuronal circuits (Dumas 2005; Sanz-Clemente et al. 2013). Notably, the change in 
NMDAR subunits is related to the shift from the greater plasticity that characterizes 
development to the greater stability that marks adult life (Bear et al. 1987; Kleinschmidt 
et al. 1987; Constantine-Patton et al. 1990; reviewed in Dumas 2005). The NR2B to NR2A 
switch in NMDAR subunit expression is conserved from frogs to mammals (Dumas 2005; 
reviewed in Paoletti et al. 2013), but it has not been widely studied in the developing 
human cerebral cortex (Scherzer et al. 1998; Henson et al. 2008; Jantzie et al. 2015). 
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 We observed that in the human fetal cortex from 16 to 24 gw, the percentage of 
NR2B-expressing RGCs decreased from 92% to 84% (p<0.05), while expression of the 
NR2A subunit increased from 70% to 91% (p<0.05). A similar change occurred in cortical 
neurons of the same developmental period. These results suggest that in human cortical 
development the switch from NR2B to NR2A begins quite early, around 22–24 gw. A 
larger shift can be assumed to occur postnatally, especially between the juvenile and 
adult stages of development, when cognitive functions mature (Dumas 2005; Sanz-
Clemente et al. 2013). A more comprehensive picture of the NR2B to NR2A switch in 
human fetal cortex requires the study of a broader range of brain tissues of different 
gestational ages as well as neonatal and adult tissue samples.  
 
NMDARs play a major role in brain development, as evidenced by the fact that 
several neurodevelopmental disorders such as schizophrenia, autism, learning 
disabilities, epilepsy and mental retardation, as well as auto-immune anti-NMDAR 
encephalitis, are thought to have a NMDAR-based pathophysiology. A number of studies 
have clearly shown that compromising the expression of the NMDAR subunits or 
manipulating their function during development can impair both the formation of neuronal 
circuits and their fine-tuning, which is essential in learning and working memory (Monyer 
et al. 1994; Dumas 2005; Groc et al. 2006; Kozela and Popik 2007; Naegele 2009; Liu et 
al. 2010; Arnsten et al. 2012). Taken together, our results show that changes in NMDAR 
subunit expression during midgestation could affect cortical development, including the 
maintenance of the balance between cortical excitation and inhibition. Further studies on  
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NMDAR subunit composition in human cortical development will contribute to a 
better understanding of the role of these receptors in brain development and in the 
pathophysiology of neuropsychiatric diseases. Such studies can be expected to provide 
the basis for the discovery of novel therapeutics that specifically modulate NMDAR 
activity.   
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Abstract  
 
Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan degradation, acts 
as an endogenous N-methyl-D-aspartate receptor (NMDAR) antagonist. Elevated levels 
of KYNA have been observed in pregnant women after viral infections and are considered 
to play a role in neurodevelopmental disorders. However, the consequences of KYNA-
induced NMDAR blockade in human cortical development still remain elusive. To study 
the potential impact of KYNA on human neurodevelopment, we used an in vitro system 
of multipotent cortical progenitors, i.e., radial glia cells (RGCs), enriched from the human 
cerebral cortex at midgestation (16-19 gw). KYNA treatment significantly decreased RGC 
proliferation and survival, and further resulted in a reduced number of cortical progenitors 
and neurons, while the number and activation of astrocytes increased. KYNA treatment 
reduced differentiation of RGCs into GABAergic neurons, while differentiation into 
glutamatergic neurons was relatively spared. Although KYNA activated astrocytes in 
enriched RGC cultures, we did not observe a significant increase in the levels of the pro-
inflammatory cytokine IL-6, which is secreted by activated astrocytes. In conclusion, 
elevated levels of KYNA play a significant role in human RGC fate determination by 
antagonizing NMDARs and the altered cell composition observed suggests a pathological 
mechanism for impairment of cortical circuitry formation in the fetal brain as seen in 
neurodevelopmental disorders such as schizophrenia.  
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 Introduction 
 
Kynurenic acid (KYNA) is an intermediate metabolite of the kynurenine pathway 
and the only naturally occurring antagonist of the glutamatergic NMDA receptor (NMDAR) 
in the human brain (Stone, 1993). In the brain, KYNA is synthesized in astrocytes by the 
irreversible transamination of L-kynurenine, the first major catabolic product of 
tryptophan. Elevated levels of KYNA have been found in the cerebrospinal fluid and in 
post-mortem brains of adult schizophrenia patients (Erhardt et al., 2001; Schwarcz et al., 
2001; Sathyasaikumar et al., 2011; Holtze et al., 2012). Both stress and infections in rats 
activated indoleamine 2,3 dioxygenase (IDO), a cytokine responsive enzyme that 
catalyzes the formation of kynurenine, which may impair brain development (Pocivavsek 
et al., 2014; Notarangelo and Pocivavsek, 2016). Furthermore, environmental influences 
during development, such as maternal influenza infection, increase the risk for 
Schizophrenia and related disorders (Wright et al., 1995; Stober et al., 2002; Limosin et 
al, 2003; Brown 2012). In rodents, KYNA can cross the placental and fetal blood-brain 
barriers (Heyes et al., 1990; Scharfman et al., 1998) and induce secretion of various pro-
inflammatory cytokines, such as interferon gamma (IFN-γ) and interleukin 6 (IL-6), from 
fetal astrocytes (Meyer et al., 2011). Additionally, in vitro studies have demonstrated that 
IFN-γ and IL-6 can activate human fetal astrocytes to synthesize increased levels of 
KYNA (Guillemin et al., 2001). Thus, exposure of the fetal brain to KYNA may establish 
a positive feed-back loop whereby KYNA levels are further enhanced (Guillemin et al., 
2001; Meyer et al., 2011; Schwieler et al., 2015).  
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Glutamate acting via NMDARs has a trophic effect during development, and may 
play an important role in determining the selective survival of neurons and their proper 
connections (LoTurco et al., 1991; Haydar et al., 2000; Balasz, 2006). This is particularly 
pertinent to a possible role for disturbed NMDAR function in schizophrenia as an 
alteration or reduction of NMDARs have been demonstrated in medication-free 
schizophrenia patients (Akbarian et al., 1996, Pilowsky et al., 2006), and abnormal 
glutamatergic activity has been reported in the pathophysiology of schizophrenia 
(Deutsch et al., 1989; Coyle, J.T., 1996; Belforte et al., 2010). Many animal models of 
schizophrenia mimic a transient NMDAR hypofunction during development using NMDAR 
antagonists such as MK-801 (Ikonomidou et al., 1999), phencyclidine (PCP; Wang et al., 
2001; Radonjic et al., 2008) and ketamine (Breier et al., 1997; Rujescu et al., 2006).  
 
Even though it is known that there is a higher incidence of schizophrenia in fetuses 
exposed to viral infections in utero (Bale et al., 2010; Brown and Derkits, 2010, Selemon 
and Zecevic, 2015), presumably due to an inflammatory response and increased levels 
of KYNA, it is still unclear how elevated levels of KYNA affect the developing human brain. 
The goal of this study was to elucidate the role of KYNA as an endogenous NMDAR 
antagonist in human fetal brain. As experimental manipulation of the developing human 
brain in vivo is not possible, we established an in vitro system to test the effects of KYNA 
on human cortical progenitor cells. 
 
Radial glia cells (RGCs) are multipotent cortical progenitor cells capable of  
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 generating all neural cell types, including subpopulations of intermediate and 
interneuron progenitors, neurons, astrocytes and oligodendrocytes (Howard et al., 2006; 
Mo et al., 2007; Mo and Zecevic, 2009; Yu and Zecevic, 2011; Lui et al., 2011; Hansen 
et al., 2010, 2013; Ma et al., 2013; Radonjic et al., 2014). Specifically, we were interested 
in how exposure to KYNA affects survival, proliferation, and specification of RGCs into 
various cell types, including cortical interneurons and pyramidal cells. We demonstrated 
that elevated levels of KYNA not only reduced survival and proliferation of RGCs, but 
significantly altered the progeny of cortical RGCs. Similar effects are observed with the 
specific blockade of NMDARs using D-APV, as demonstrated in Chapter 4. Treatment 
with KYNA promoted gliogenesis at the expense of neurogenesis, and increased 
activation of astrocytes. These combined effects of KYNA could impair cortical circuitry 
formation in utero and in doing so contribute to the pathophysiology of 
neurodevelopmental illnesses, possibly including the adult-onset disorder of 
schizophrenia. 
 
Materials and Methods 
 
Human Fetal Brain Tissue 
 
Human fetal brain tissue (n = 4), free of any developmental abnormalities,  at 16 
to 19 gw was obtained with the approval of the Ethics Committees and with written 
informed consent, from Human Developmental Biology Resource (Newcastle University,  
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Newcastle upon Tyne, England) and the Tissue Repository of The Albert Einstein 
College of Medicine (Bronx, NY, USA). The age of the tissue was determined by the 
following criteria: crown-rump length, weeks after ovulation, and anatomical landmarks. 
The tissue was transported on ice in Hank’s Balanced Salt Solution (HBSS; Life 
Technologies, Grand Island, NY, USA) from the aforementioned brain repositories to the 
lab. A small piece (1 cm2) of the dorsal telencephalic region was used to generate 
dissociated cell cultures (Zecevic et al. 2005; Radonjic et al., 2014).   
 
Dissociated Mixed Cell Culture and Enrichment of RGCs 
 
A previously published protocol (Mo and Zecevic, 2007) was used to establish 
dissociated mixed cell cultures. As briefly described here, the isolated tissue was 
dissociated mechanically and enzymatically at 37°C for 30 minutes with 0.025% trypsin 
(Gibco, Beverly, MA, USA), followed by addition of DNase (Sigma-Aldrich, St Louis, MO, 
USA; 2 mg/mL), washing with HBSS (Life Technologies) and suspension in proliferation 
medium (PM; Figure 10A). The PM consisted of DMEM/F12 (Life Technologies) 
supplemented with 10 ng/mL of basic fibroblast growth factor (bFGF, Peprotech, Rocky 
Hill, NJ, USA), 10 ng/mL of epidermal growth factor (EGF, Millipore, Billerica, MA, USA), 
and B27 (Life Technologies). Seven to ten days after plating, the cells proliferated in PM 
and reached 80% confluency whereupon they were used for to generate RGC cultures.  
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 Figure 10. Enriched RGCs from human fetal cortex using MACS. (A) Dissociated mixed 
cell cultures are established from the telencephalic wall (red box), and RGCs are enriched 
from these cultures through magnetic sorting (MACS) using anti-CD15 micro-beads. (B) 
Enriched RGCs are co-labeled for CD15 and radial glia markers BLBP or GFAP after 3 
DIV of proliferation. Nuclear stain: bis-benzimide (BB). 
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RGCs were isolated from mixed cell cultures using the cell surface glycan marker 
CD15 via MACS columns (Miltenyi Biotec, Auburn, CA, USA) with magnetic anti-CD15 
antibody beads (Mo et al. 2007; Radonjic et al., 2014). Enriched RGCs were co-labeled 
for surface antigen CD15 and either brain lipid binding protein or glial fibrillary acidic 
protein, both markers of RGCs (Figure 10B), demonstrating that the enriched RGC 
cultures were 98% pure. RGCs were plated on poly-D-lysine (Sigma-Aldrich) coated 
coverslips (12 mm) at a density of 250,000 cells/ml and were used for 
immunocytochemistry. Poly-D-lysine coated six wells (10 cm2 growth area/well) were 
plated with 2 million cells/ml and the collected cell lysates were used for total protein and 
RNA isolation. After 3 DIV in PM, the culture medium was change to differentiation 
medium (DM) devoid of growth factors and cells were allowed to differentiate for 7 DIV.  
 
Pharmacological Treatments of Cell Cultures  
 
RGC cultures were treated with each of these substances: KYNA, NMDAR-specific 
antagonist D-amino phosphonovalerate (D-APV), and nicotinic acetylcholine receptor 
antagonist Tubocurarine chloride (TBC), in order to determine if the effect of KYNA was 
mediated through NMDARs or nAChRs. Concentration-response curves were first plotted 
48 h after RGC cultures underwent treatments with eight different concentrations (0.001 
μM to 100.0 μM) of KYNA (Sigma Aldrich), D-APV (Tocris Biosciences, Bristol, UK) and 
TBC. KYNA was dissolved in DMSO (Dimethyl sulphoxide, Sigma Aldrich), and therefore 
two sets of controls were maintained: 1) RGCs grown only in PM, 2) RGCs grown in PM  
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 containing DMSO. In all analyzed experiments there was no difference between control 
PM and PM+DMSO, hence PM+DMSO results were represented in graphs as the control. 
The effective concentration at which 50% of the cell population was affected (EC50) was 
determined in both assays to decide the treatment concentrations to be used for further 
experiments, where cells were analyzed after 3 DIV in PM, and after 7 DIV in DM.  
 
Cell Survival Assay 
 
A live/dead assay (Molecular Probes, Eugene, OR, USA) was performed after 48 
h of KYNA treatment to assess its effect on cell viability. The kit enables detection of live 
cells via the cell-permeant molecule calcein acetoxymethyl that gives a green 
fluorescence in the presence of intracellular esterases. Dead cells which have lost the 
intact cell membrane appear red due to incorporation of an ethidium homodimer into their 
degrading nucleic acids.  
 
Proliferation Assay 
 
At the end of the 48 h KYNA treatment period, cells were fixed and immunostained 
with anti-Ki67 antibody. Ki67 is a marker of cells undergoing mitotic divisions or 
proliferation. The percentage of Ki67+ cells was determined from the total number of cells 
marked with the nuclear stain bisbenzimide (BB). 
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Table 5 Antibodies used for immunocytochemistry and Western blotting. 
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Primary 
Antibody 
Cell Type 
Identified 
Species Dilution 
Catalog 
number 
Company 
CD15 
Radial Glia 
(RGC) 
mouse 1:100 MS-1259-P 
Thermo 
Scientific 
BLBP RGC rabbit 1:250 ab32423 Abcam 
GFAP 
RGC, 
Astrocyte 
mouse, 
rabbit 
1:3000 Z0334 Dako 
Tbr2 
Intermediate 
Progenitor 
rabbit 1:200 ab23345 Abcam 
Nkx2.1 
Interneuron 
Progenitor 
rabbit 1:200 ab76013 Abcam 
βIII tubulin Neuron 
mouse, 
rabbit 
1:5000 PRB-435P 
Sigma-
Aldrich 
Tbr1 
Glutamatergic 
Neuron 
rabbit 1:200 
20932-1-
AP 
Proteintech 
GABA Interneuron rabbit 1:500 A2052 
Sigma-
Aldrich 
CalR Interneuron rabbit 1:500 7699/4 Swant 
Ki67 
Proliferating 
Cells 
rabbit 1:500 ab15580 Abcam 
GAPDH Housekeeping mouse 1:5000 AB2302 Millipore 
NR1 - mouse 1:200 P35439-2 NeuroMab 
 Immunocytochemistry (ICC) 
 
Cells growing in vitro on coverslips were fixed with 4% paraformaldehyde, washed with 
PBS (phosphate buffer saline), blocked (0.2% bovine serum albumin (BSA), 0.01 % Triton 
X-100, PBS) for 1 h at RT, and incubated with two primary antibodies raised in different 
species (typically mouse and rabbit) (Table 5) at 4oC overnight. The following day, 
appropriate secondary antibodies were applied for 2 h at RT, followed by the nuclear stain 
BB for 1 min. All immunostained coverslips were mounted using the anti-fade reagent 
Fluoromount-G (Southern Biotech, Birmingham, AL, USA) to preserve the fluorescence.  
 
Image analysis and statistical tests  
 
Immunolabeled samples were visualized using an Axioscope microscope (Zeiss, 
Germany) together with Axiovision software and photographed using a digital camera. 
During acquisition of images of double immunolabeled sections the focus, brightness and 
contrast were kept constant.  The images were taken with 63X lens and assembled in 
Adobe Photoshop (v. 7.0), with consistent quality adjustments for contrast, brightness and 
color balance. Immunolabeled cells from 10 predesignated adjacent optical fields and 
from four different human samples (n=4, tissue samples of different gestational age) per 
experiment were analyzed using Adobe Photoshop (v. 7.0). We quantified each marker 
in its respective channel in Photoshop, and then by switching channels in Photoshop 
looked for cells that show immunoreaction for both applied antibodies. The total cell  
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number in the optical fields was determined by quantifying cell nuclei labeled with a 
nuclear dye BB. The percentage of double labeled cells was then calculated from a total 
cell count.  
 
Western Blot (WB) 
Cells were homogenized in lysis buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 
1% NP-40, 1 mM phenylmethylsulfonyl fluoride, Sigma Aldrich, and protease and 
phosphatase inhibitors (PMSF (1 mM), NaF (5 mM), Na-orthovanadate (1 mM), PIC (1 
mM; Thermo Scientific)) on ice for 30 min, centrifuged at 14000 × g for 15 min at 4oC, and 
the supernatants were collected as the cell lysates. Protein concentration was determined 
using the BCA colorimetric assay (Thermo Scientific). Proteins were separated on a 4-
15% gradient polyacrylamide gel (Bio-Rad, Portland. ME, USA) at 110 volts for 75 min, 
and were transferred onto the polyvinylidene fluoride (PVDF) membrane at 100 volts for 
60 min. After blocking with 5% milk in TBS-T, the membrane (blot) was incubated with 
primary antibodies diluted in blocking buffer at 4oC overnight. The blot was washed with 
1X TBS-T (10% Tween, PBS, 0.1% TritonX-100, distilled water), and incubated with 
secondary antibodies for 2 h at RT. Blots were analyzed for the proteins of interest (Table 
5). Blots were incubated with SuperSignal West Dura Extended Duration Substrate 
(Thermo Scientific), and were imaged on ChemiDoc MP (Bio-Rad) digital imaging system, 
taking images that were not saturated. Protein levels were quantified by densitometric 
analysis and normalized to GAPDH levels, determined using an anti-GAPDH antibody 
(1:5000).  
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 Reverse-transcriptase polymerase chain reaction (RT-PCR) and quantitative PCR 
(qPCR) 
 
Cells were treated with ice-cold TRIZOL® reagent (Invitrogen, Carlsbad, CA, USA; 1 ml/ 
10 cm2) and were homogenized using three freeze-thawing cycles with each cycle 
consisting of samples remaining in dry ice for 10 minutes followed by incubation in ice for 
10 minutes. Chloroform (200 μl) was added to the homogenates, and tubes were 
vortexed, incubated (15 min at 4 oC), and centrifuged (13000 X g for 15 min at 4 oC). The 
upper transparent phase was collected in sterile tubes, incubated with isopropanol (500 
μl/ tube; 20 min at RT), and centrifuged (13000 X g for 15 min at 4oC). The pellets were 
incubated with 75% ethanol (4 oC) and centrifuged (13000 X g for 15 min). The pellets 
containing RNA were air dried and dissolved in 5% RNase Out solution. RNA 
concentrations were determined using the NanoDrop technology (260/280 ratios obtained 
were between 1.93 and 2.0). cDNA was synthesized by RT-PCR using the First Strand 
Synthesis SuperScript III kit (Invitrogen). The SYBR Green (Applied Biosystems, 
Cheshire, UK) protocol was used to analyze the expression levels of mRNA from the 
cDNA samples (Table 6) by performing qPCR using the CFX96 Connect™ thermocycler 
(Bio-Rad). The qPCR protocol involves a heating step to 95oC for 2 min followed by 40 
cycles at 95oC for 15 seconds, at 55oC for 15 seconds, and at 68oC for 20 seconds. Cycle 
of threshold (Ct) values were used to calculate the ΔΔCt values, and the formula 2-ΔΔCt 
was used to determine the mRNA expression level relative to the control sample which 
has an arbitrary value of 1.  
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Table 6 Primers used for qPCR 
Genes 
Cell Type 
Identified 
Forward Primer Sequence Reverse Primer Sequence 
Nestin RGC 
5`-GCC CTG ACC ACT 
CCA GTT TA-3` 
5`-GGA GTC CTG GAT TTC 
CTT CC-3` 
Tbr2 
Intermediat
e 
Progenitor 
5`-GGG CAC CTA TCA 
GTA CAG CCA-3` 
5`-AAG GAA ACA TGC GCC 
TGC-3` 
Nkx2.1 
Interneuro
n 
Progenitor 
5`-CAC GCA GGT CAA 
GAT CTG GTT-3` 
5`-TTG CCG TCT TTC ACC 
AGG A-3` 
Neuroge
nin 
Neuron 
5`-GCATCAAGA 
AGACACGCAGACTGA-3` 
5`-
TCTCGATCTTGGTTAGCTTG
GCGT-3` 
Tbr1 
Glutamater
gic neuron 
5`-TCT GAG CTT CGT 
CAC AGT TTC-3` 
5`-GCT GTT GTA GGC TCC 
GTT G-3` 
Gad65 
Interneuro
n 
5`-CCT CAA CTA TGT 
CCG CAA GAC-3` 
5`-TGT GCG AAC CCC ATA 
CTT CAA-3` 
Gfap Astrocyte 
5`-CTG CGG CTC GAT 
CTG GTT-3` 
5`-TCC AGC GAC TCA ATC 
TTC CTC-3` 
Grin1 - 
5`-CCA GTC AAG AAG 
GTG ATC TGC AC-3` 
5`-TTC ATG GTC CGT GCC 
AGC TTG A-3` 
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 Sandwich Enzyme Linked Immunosorbent Assay (Sandwich ELISA) 
 
The eBioscience High Sensitivity human anti-IL6 ELISA (San Diego, CA) kit was 
used for the sandwich ELISA experiments on dissociated mixed cell cultures prepared 
from four fetal brains (16-19gw). The assay was performed according to manufacturer’s 
instructions. We used Origin to plot the standard curve and analyze results from the 
ELISA experiment. 
 
Statistics 
 
All data were expressed as mean + standard error of mean (SEM). Mean, SEM 
and p-values were calculated in Microsoft Excel. For all Western Blot and qPCR 
experiments, triplicate values were averaged across the four brains (n=4; 16-19 gw) for 
each treatment to obtain a mean value for each treatment. The means obtained from each 
brain in a treatment group were averaged to obtain a group mean. Variations were 
expressed as the mean ± standard error (SEM). One-way ANOVA followed by 
Bonferroni’s post-hoc test was used to evaluate statistical significance, defined as a p 
value <0.05.  
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Results 
 
Cortical Progenitors and Neurons express NR1 at midgestation  
 
Using the enriched dorsal RGCs cultures (see Methods; Figure 10) we explored whether 
isolated RGCs express NMDARs, particularly the obligatory subunit NR1, as KYNA has 
specific affinity towards the glycine site of NR1 subunit (Zhuravlev et al., 2007). Indeed, 
cultured human RGCs express the NR1 subunit (Figure 11) after 3 DIV of proliferation 
and 7 DIV of differentiation in all fetal brains studied (n=4, 16-19 gw). In order to determine 
which progenitor subtypes express the NR1 subunit after 3 DIV we used double 
immunolabeling with antibodies against NR1 and the markers of cortical progenitors 
(Figure 11A). We demonstrated that RGCs labeled with BLBP, intermediate progenitors 
labeled with Tbr2, and a subpopulation of interneuron progenitors labeled with Nkx2.1, all 
express the NR1 subunit (Figure 11B; top panel). After 7 DIV of differentiation, the newly 
generated neurons labeled with βIII tubulin, and also with Tbr1 or GABA, markers of 
glutamatergic and cortical interneurons, respectively, express NR1 (Figure 11B; bottom 
panel). In humans, GFAP is a marker for differentiated astrocytes, and both cell types 
express NR1 subunit. Thus, based on these co-labeling experiments, we conclude that 
at midgestation, both cortical progenitors, two neuronal subtypes, glutamatergic and 
interneurons, and astroglia cells express the NR1 subunit of NMDARs.  
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Figure 11. Cell types that express NR1 subunit at mid-gestation. (A) Timeline showing 
that NR1 expression was analyzed on progenitors after 3 DIV in PM and on mature cell 
types after 7 DIV in DM; n =4. (B) Representative double immunolabeling images taken 
from 17 gw cultures for NR1 (green) with either progenitor, neuronal or astroglial markers 
(red). After 3 DIV in PM, NR1 was expressed on BLBP+ RGCs, Tbr2+ intermediate 
progenitors, Nkx2.1+ interneuron progenitors, and on GFAP+ astroglia. After additional 7 
DIV in DM, NR1 was expressed on neurons labeled with βIII tubulin, Tbr1, GABA, and on 
astrocytes labeled with GFAP. Double-labeled cells are yellow. Nuclear stain: BB. 
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KYNA Affects Cell Survival and Proliferation via blockade of NMDARs  
 
We further examined the effects of KYNA on proliferation and survival of human 
RGCs. KYNA antagonizes the NMDARs as well as the nAChRs, though at significantly 
different concentrations. To determine if the effect of KYNA on cell cycle and cell death 
was mediated through NMDARs or nAChRs, we used receptor specific antagonists: D-
APV is specific to NMDARs and TBC for nAChRs (Figure 12A).  
 
Response curves were first plotted 48 h after RGC cultures underwent treatments 
with eight different concentrations of KYNA, D-APV, and TBC. The effect of KYNA on 
RGCs proliferation and on cell survival was measured, and the effective concentration at 
which 50% of the cell population was affected (EC50) was determined in both assays. 
Considering that concentration 0.05 μM effectively induced 50% cell death and 
concentration 0.01 μM effectively inhibited 50% of cell proliferation (Figure 12B,C), we 
used the following treatment concentrations for further experiments: 0.001 μM, 0.005 μM  
and 0.01 μM of KYNA for 48 h. Furthermore, KYNA concentration-response curves in 
both assays were similar to that of D-APV while TBC curves were shifted to the right, 
suggesting that in human RGC cultures KYNA acts very similar to the NMDAR-specific 
antagonist D-APV.  
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Figure 12. Concentration-response curve for the in vitro KYNA treatment. (A) Timeline of 
the experiment. (B) The live/dead assay: live (green) and dead cells (red) for control 
(DMSO) and drug treatments. (C) Ki67+ proliferating cells (red); nuclear stain BB (blue); 
n =4; p < 0.05 between DMSO and each treatment. Error bars represent mean+SEM; 
DMSO-Dimethyl sulfoxide,TBC- Tubocurarine chloride, D-APV- D-amino 
phosphonovalerate.  
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KYNA alters RGC specification 
 
To examine the effects of KYNA on the specification of human cortical progenitors, 
we followed the progeny of RGCs after 3 DIV of proliferation. Real-time PCR revealed 
that after KYNA treatment expression of genes specific to progenitor subtypes is 
decreased in a concentration-dependent manner, while expression of the astroglial gene, 
Gfap is increased with the highest KYNA concentration of 0.01 μM (p < 0.05; Figure 13A).  
Protein expression, examined in whole cell lysates using Western blotting, revealed that 
treatment with KYNA significantly reduced expression levels of proteins specific for 
cortical progenitors. While only the highest concentration of KYNA (0.01 μM) had 
significant (p < 0.05) effects on RGC protein BLBP and intermediate progenitor protein 
Tbr2, all three concentrations of KYNA reduced expression of protein Nkx2.1 present in 
a subpopulation of cortical interneuron progenitors (p < 0.05). In accordance with gene 
expression levels, astroglial protein GFAP showed an increase after KYNA treatment in 
a concentration-dependent manner (p < 0.05; Figure 13B, C).  
 
Looking at the effects of KYNA on the cell types using immunocytochemistry, we 
found that the percentage of BLBP+ RGCs and Tbr2+ intermediate progenitors from all 
cells in the culture were significantly reduced with the two highest concentrations (0.005 
μM and 0.01 μM), while all three concentrations of KYNA significantly decreased the 
percentage of Nkx2.1+ interneuron progenitors (p<0.05). These results were in line with 
those observed from the qPCR and Western blotting experiments. Similar to data on gene  
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Figure 13. Blocking NMDAR affects cell fate determination in vitro. (A) KYNA treatment 
decreased progenitors but increased astroglia specific gene expression in a 
concentration-dependent manner, (B) Western blot from 17 gw KYNA treated cell lysates, 
and (C) the densitometric analysis showed a decrease in progenitor, but increase in 
astroglia protein expression in a concentration-dependent manner. (D) Representative 
images at 17 gw for immunolabeling with specific progenitor and astroglia markers (red), 
and nuclear stain: BB (blue). (E) The immunolabeling quantification showed a decrease 
in percentage of progenitor subtypes, but an increase in astroglia population (n=4; p < 
0.05). Scale bar 50μm.  
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and protein expression, we found a significant increase in the GFAP+ astroglial population 
in KYNA treated cultures (p < 0.05; Figure 13D, E). These results indicate that KYNA 
significantly altered the specification of the cortical radial glia progenitor cells by reducing  
the number of progenitor subtypes (Tbr2, Nkx2.1)  while increasing the number of GFAP+ 
astroglial cells, the first type of glia to appear once neurogenesis is completed in vivo. 
This alteration in the progenitor specification timeline is likely to alter the downstream 
process of neurogenesis and gliogenesis. . 
 
KYNA modifies the process of neuronal differentiation 
 
Since KYNA negatively affected RGCs and altered their specification process, we 
hypothesized that the process of progenitor cells differentiating into cortical neurons is 
also affected. In order to test our hypothesis, we added differentiation medium (DM) to 
our progenitor cell cultures for 7 DIV and then assessed their differentiation into either 
neurons or astrocytes.  
 
Gene expression analysis using qPCR showed that KYNA decreased expression 
of neuronal genes Neurogenin 1/2, Tbr1, and Gad65 in a concentration-dependent 
manner, but increased expression of astrocytic gene Gfap (p < 0.05; Figure 14A). This 
finding was further supported by the decrease in neuronal proteins βIII tubulin and Tbr1, 
but an increase in astrocytic protein GFAP after KYNA treatment (p < 0.05; Figure 14B, 
C).  
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 To analyze the effect on specific cell-types, we performed immunocytochemistry using 
antibodies specific to neuronal proteins. We observed a significant decrease in the 
number of cells labeled with neuronal markers (β-III-tubulin, Tbr1, GABA, Calretinin) and 
this decrease was KYNA concentration-dependent. Moreover, the decrease of 
GABAergic neurons was 50% and glutamatergic (Tbr1) neurons 17% comparing to 
controls, suggesting a greater effect of KYNA on interneuron versus glutamatergic 
neurogenesis. Once again, we found an increase in the number of GFAP+ astrocytes, 
indicating a drive towards astrocyte formation (p < 0.05; Figure 14D, E). We have not, 
however, observed any differences in oligodendrocyte progenitors (O4+ cells) or mature 
oligodendrocytes (MBP+ cells) in our KYNA treated cultures (not shown).  
 
Combined results obtained with a battery of methods demonstrated that KYNA 
influenced the RGC specification and differentiation process by increasing the astroglial 
cell population at the expense of neuronal cells. Developmentally, this shift in gliogenesis 
occurring before neurogenesis could be detrimental to cortical circuitry formation and 
function.  
 
KYNA treatment Increases the population of Reactive Astrocytes  
 
It has been previously reported that KYNA triggers activation of astrocytes and 
generates an inflammatory response that involves secretion of pro-inflammatory 
cytokines (Guillemin et al., 2001; Meyer et al., 2011). To test this possibility, we  
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 Figure 14. Differential effect of KYNA treatment on neural cell types. (A) q-PCR showed 
that KYNA treatment decreased neuronal specific (Neurogenin, Tbr1, Gad65), but 
increased astrocytic gene (Gfap) expression (B) Western blot from 17 gw KYNA treated 
cell lysates, and (C) Densitometric analysis showed a decrease in expression for neuron 
specific proteins, but an increase for astrocytic protein (D) Immunostaining at 17 gw for 
neuron and astrocytic markers (red); nuclei labeled with BB (blue). (E) Quantification of 
the immunolabeling showed a decrease in neuronal cell populations but an increase in 
the astrocyte cell population (n=4; p < 0.05).  
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immunolabeled KYNA treated RGC cultures with an antibody to S100β, a cytoplasmic 
marker for reactive astrocytes (Figure 15A). The quantification of the number of S100β+ 
cells immediately after the 48 h KYNA treatment revealed that treatment with KYNA 
induced a significant increase in S100β+ cells, from 0.5% in control conditions to 30% 
when treated with 0.01 μM KYNA (p < 0.05; Figure 15B). These S100β+ astrocytes were 
large cells with multiple processes. Reactive astrocytes are a well-known source of pro-
inflammatory cytokines, one of which is IL-6, a primary cytokine released in almost all 
inflammatory responses (Guillemin et al; 2001; Islam et al., 2009). Since we observed a 
strong gliosis reaction in our KYNA-treated RGC cultures, we determined the level of 
secreted cytokine IL-6.  We examined, using ELISA, the IL-6 concentration in our media 
obtained from KYNA treated RGC cultures at two time points, 24 h and 48 h immediately 
after the treatment. We observed that even the highest dose of KYNA did not induce 
secretion of a significantly high amount of IL-6 after 24 h (0.001 pg/ml in control versus 
0.003 pg/ml in 10 nM KYNA, p = 0.07), and 48 h (0.003 pg/ml in control versus 0.005 
pg/ml in 10 nM KYNA, p = 0.09). However, previous studies with human subjects have 
reported that the levels of IL-6 in the cerebrospinal fluid in normal patients is ~1 pg/ml, 
while their age and sex matched schizophrenic counterparts show levels closer to 4 pg/ml 
of IL-6 (Garver et al., 2003; Schwieler et al., 2015). Taking these small levels of IL-6 into 
consideration, our in vitro IL-6 levels demonstrate a potentially important upward trend 
(Figure. 15C). We  
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 Figure 15. KYNA activates astrocytes. (A) Immunocytochemistry for S100β, a marker for 
reactive astrocytes, was performed on KYNA treated RGC cultures. (B) Quantification of 
the immunocytochemistry reveals that KYNA treatment triggered generation of reactive 
astrocytes in a dose-dependent manner after 48 h, and cultures partly recovered after 7 
DIV in DM. (C) KYNA treated RGC cultures at 24 and 48 h time points did not exhibit a 
significant increase in IL-6 secretion as compared to control. Nuclear stain: BB; n =4; 
p<0.05. Error bars represent mean+SEM. 
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 measured concentration of secreted IL-6 in the medium after 24 and 48 h after KYNA 
treatment, and failed to observe significant increases in levels of IL-6 in KYNA treated 
cultures, at both time points (Figure 15C). Our failure to observe differences in IL-6 levels 
between different concentrations of KYNA could be a consequence of the homogeneous 
RGC cultures we use to study effects of KYNA treatment, since RGC cultures could be 
incapable of producing a high enough number of reactive astrocytes needed to secrete 
large amounts of detectable IL-6 levels.  
 
Discussion 
 
In the present study, we explored the effects of KYNA on human cerebral cortical 
development in cell cultures derived from midgestational human tissue. Previous studies 
in rodents (Malatesta et al., 2000; Miyata et al., 2001; Noctor et al., 2001; Noctor et al., 
2004), and humans (Hansen et al., 2010; Clowry et al., 2010; Betizeau et al., 2013, Malik 
et al., 2013; Radonjic et al., 2014) have shown significant species-specific differences  
demonstrating critical need for studies of cortical development in human cultures. Three 
major findings from this study demonstrate that KYNA, similar to the NMDAR-specific 
antagonist D-APV, significantly alters proliferation, specification and differentiation of 
cortical cells generated from enriched RGC cultures. First, after KYNA treatment, RGC 
proliferation and survival decreased resulting in a reduced number of cortical progenitors 
(Nkx2.1+ and Tbr2+ cells), neurons (βIII tubulin+), and interneurons (GABA+, CalR+). 
Second, KYNA treatment effectively pushed the specification of RGCs toward the  
 99 
astroglial lineage, as evidenced by the increase in number of GFAP+ cells after 3 DIV of 
proliferation. Third, not only did the number of GFAP+ astrocytes increase, but in addition, 
astrocytes were activated as demonstrated by morphological changes and S100β 
labeling. In sum, these results indicate that altered levels of KYNA in human gestation, 
as can result from maternal infection and immune activation, may have profound effects 
on cortical development. 
 
KYNA disrupts neurogenesis and reduces the pool of cortical progenitors in vitro 
 
KYNA is a product of the kynurenine pathway, the main metabolic route of 
tryptophan degradation, and is responsible for a broad spectrum of effects, including the 
endogenous regulation of neuronal excitability and the initiation of immune tolerance. 
KYNA is the only known endogenous antagonist of the NMDAR in vivo, and binds strongly 
to the NR1 subunit (Kessler et al., 1989; Wang et al., 2006).  However, KYNA also inhibits 
nAChRs (Hilmas et al., 2001; Alkondon et al., 2004), and both NMDAR and nAChRs are 
expressed early during human development (4-5 gw; Kostovic et al., 1989; Hellstrom-
Lindahl et al., 1998; Suzuki et al., 2006). Therefore, it was necessary to distinguish toward 
which receptor KYNA exhibits a stronger affinity, in order to study KYNA effects on the 
early developing brain. In this study, we showed that in RGCs, KYNA has a higher affinity 
for NMDARs over nAChRs, corroborating previous studies that showed KYNA’s inability 
to block nAChR-dependent electrical activity in cultured adult rat cortical and hippocampal  
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 cells (Hilmas et al., 2001; Mok et al., 2009; Dobelis et al., 2012).  
 
During embryonic development in rodents and humans, NMDARs are important 
for proliferation of neural stem cells, their differentiation into neurons and glia, and proper 
migration of the differentiated cell types to their correct position in the six-layered cerebral 
cortex (Manent et al., 2005, Suzuki et al., 2006, Toriumi et al., 2012). In vivo blockade of 
NMDARs during rat cortical development induces apoptosis of neuronal and glial cells 
leading to severe neurodegeneration and ultimately death of the animal (Ikonomidou et 
al., 1999). In vitro, we observed that blocking NMDARs with D-APV induces similar effects 
of increasing cell death and decreasing neuronal differentiation (Chapter 4). Here, we 
show that elevated levels of KYNA, an endogenous NMDAR antagonist, increased cell 
death of cortical progenitors and decreased RGC proliferation, showing the detrimental 
effects of elevated KYNA levels on human cortical progenitors during the second trimester 
of gestation. 
 
KYNA-induced changes in cell fate determination  
 
An important issue is whether KYNA has differential effects on generation of 
principal neurons and interneurons in the developing cortex. This was important because 
our results with NMDAR-specific antagonist D-APV showed that GABAergic neurons are 
more sensitive to NMDAR blockade than Tbr1+ glutamatergic neurons (Chapter 4). To 
study this question, we used various transcription factors to label distinct neuronal  
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populations in vitro. In accordance with previous studies (Rakic and Zecevic 2003; 
Zecevic et al. 2005; Jakovcevski et al. 2011), we found that RGC cultures in this study, 
successfully generated progenitors of the glutamatergic (Tbr2+) and interneuronal 
(Nkx2.1+) progenitors (Bayatti et al., 2008b; Yu and Zecevic 2011; Malik et al., 2013; 
Pollen et al., 2015) that further give rise to glutamatergic neurons (Tbr1+) and 
interneurons (GABA+) (Englund et al., 2005; Yu and Zecevic 2011). Most notably, we 
have shown that a KYNA-induced decrease in Nkx2.1 and Tbr2 expression resulted in a 
decrease of GABAergic interneurons which was more pronounced than the decrease of 
Tbr1+ glutamatergic neurons. These data suggest that a KYNA-induced alteration in the 
cortical progenitor pool disrupts neurogenesis in a manner similar to that observed with 
NMDAR-specific antagonist D-APV. Such changes can subsequently affect the 
proportionate balance of cortical cell types and the ensuing cortical circuitry formation. 
 
KYNA failed to elicit a pro-inflammatory response in cortical progenitor cultures  
 
Mounting evidence suggests a link between maternal immune activation and 
neuropsychiatric illness (Gilmore and Jarskog, 1997; Buka et al., 2001). The KYNA-
mediated NMDAR blockade favored astrocyte generation, as had been shown previously 
in human fetal astrocyte cultures (Guillemin et al. 2001), and in addition induced the 
activation of resting astrocytes in both RGC cultures and mixed cell cultures. The 
morphology of S100β+ cells changed, and their number increased, implying a pro-
inflammatory response. Interestingly, astrocytic hypertrophy has been reported in the  
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 prefrontal cortex of patients with neuropsychiatric disorders (Rajkowska et al., 2001), 
indicating that reactive astrocytic changes can be a major component of disease 
pathology.  
 
Even though we showed increased numbers of reactive astrocytes in our enriched 
RGC cultures, we did not observe any increase in the levels of secreted IL-6, a pro-
inflammatory cytokine, in our RGC culture medium following KYNA treatment. This was 
an unexpected outcome since several reports in mice have indicated that KYNA causes 
the release of inflammatory cytokines, especially IL-6 and IFN-γ (Islam et al., 2009). 
Moreover, in vitro, both IFN-γ and IL-6 activate human fetal astrocytes to synthesize large 
amounts of KYNA (Guillemin et al., 2001; Islam et al., 2009; Meyer et al., 2011; Schwieler 
et al., 2015). Activation of cytokines is directly relevant to schizophrenia as studies in 
human subjects found elevated levels of IL-6 in the cerebrospinal fluid of Sch patients in 
comparison to their age and sex-matched healthy counterparts (Garver et al., 2003; 
Schwieler et al., 2015). These studies suggest that there are certain cell types present in 
vivo that are responsible for the increased amounts of IL-6, and this further suggests that 
our enriched RGC cultures are devoid of those cell types. To determine if KYNA treatment 
indeed elicits a pro-inflammatory response during human development, we need to 
establish cultures consisting of all cell types in the human fetal brain. Such cultures called 
mixed cell cultures will enable us to completely understand the mechanistic pathway 
through which KYNA functions in human cortical development.  
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Consequences of elevated KYNA levels during fetal neurodevelopment  
 
Metabolites of the kynurenine pathway have important roles in the CNS, and recent 
data imply a role in brain development as well (reviewed in Notarangelo and Pocivavsek, 
2016). Physiological levels of KYNA are higher in the developing brain compared to the 
immediate postnatal period and adulthood (Beal et al., 1992; Walker et al., 1999; 
Ceresoli-Borroni and Schwarcz, 2000). It has been suggested that KYNA might protect 
the fetal brain from over-excitation via NMDARs (Badawy, 2014). At the same time, 
glutamate via activation of NMDARs has an important trophic role in neurodevelopment. 
Various insults during pregnancy can lead to direct physiological changes in the fetal 
environment, thereby influencing the normal course of prenatal brain development. For 
example, the anesthetic ketamine and drugs of abuse such as PCP and ethanol 
antagonize normal function of fetal cortical NMDARs (Anis et al., 1983; Krystal et al., 
1994; Lahti et al., 1995; Lieberman et al., 2012; Xiang et al., 2015). These disruptions 
may have long-lasting consequences for subsequent brain and behavioral development 
and might lead to structural and functional brain abnormalities in adult life (Iaccarino et 
al., 2013).  
 
Even though it is well established that KYNA acts as an antagonist of NMDAR and 
nAChR, the consequences of pathological levels of KYNA in the developing brain have 
not been fully explored. Our in vitro study shows that KYNA negatively influences the 
proliferation of human RGCs and pushes RGC specification towards astrocytes, versus  
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 neurons, observations that resound the effects of D-APV on human RGC progenitors 
(Chapter 3). In addition, higher KYNA concentrations, while negatively impacting both 
interneurons and principle neurons, results in larger deficits in GABA+ interneurons (50% 
decrease compared to control) compared to a Tbr1+ subpopulation of projection neurons 
(17% decrease compared to control). The preferential vulnerability of interneurons might 
be clinically relevant since impaired function of cortical interneurons is reported in 
neurodevelopmental disorders including schizophrenia and autism spectrum disorder 
(DeFelipe, 1999; Gleeson and Walsh, 2000; Akbarian et al., 1995; Knable, 1999; Lewis 
and Levitt, 2002; Levitt, 2003; Baraban and Tallent, 2004; Lewis et al., 2005). In our study 
human cortical progenitors were isolated at mid-gestation (16-19 gw), an important period 
of active neurogenesis when upper cortical layers are formed (Hill and Walsh, 2005). As 
these layers are crucial for formation of cortico-cortical connections and subsequently for 
emergence of higher brain functions, interference with glutamate receptor function at this 
developmentally sensitive period may lead to widespread effect on formation of the 
cortical circuitry. Together, these changes can have a negative impact on maturation of 
cortical functions during adolescence, a stage when cognitive executive functions, such 
as planning, rational thinking, attention, and emotion-related impulsivity control develop 
and a time point at which schizophrenia symptoms often first manifest (Uhlhaas, 2011).   
 
Certainly, in vitro systems have limitations, and further studies are needed to 
discern the complexity of developmental disruption caused by elevated levels of the 
endogenous NMDAR antagonist, KYNA. Since live human fetuses cannot be used for  
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research purposes, our in vitro system of human progenitor cells enriched from aborted 
fetuses serves as an innovative tool for understanding the possible effects of endogenous 
molecules, when present at pathological levels, on human fetal cortical development.  
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Chapter 4 
 
Effects of the NMDAR specific antagonist D-APV on human cortical development 
 
Note: Experiments in this Chapter are similar to those in Chapter 3, and help us compare 
results between D-APV, and the endogenous excitatory receptor antagonist KYNA.  
 
Abstract 
 
The NMDAR specific antagonist D-APV, is a fast-acting, competitive antagonist 
that binds to the glutamate-binding site on the NR2 subunit of the NDMAR. NMDARs are 
important for many cellular processes such as LTP, working memory, and cell survival in 
adulthood. Studies have shown that NMDARs are important in fetal development since 
autoantibodies generated against NMDARs hamper brain development and lead to an 
autoimmune disease called anti-NMDAR-encephalitis. However, the exact consequences 
of the NMDAR blockade still remain unknown in human cortical development. To study 
the potential role of NMDARs in human neurodevelopment, we used an in vitro system of 
multipotent cortical progenitors, i.e., radial glia cells (RGCs), enriched from human 
cerebral cortex at mid-gestation (16-19 gestational weeks; gw). Treatment with D-APV 
significantly reduced the population of proliferating progenitors in a concentration-
dependent manner. D-APV treatment significantly decreased progenitor populations after 
3 days in vitro (DIV) and impeded neuronal differentiation after 7 DIV. Moreover, D-APV 
favored the specification of progenitors into the glial lineage by increasing the number of 
astrocytes, and more importantly, reactive astrocytes. Thus, blocking NMDARs with D-
APV negatively influences the proliferation, specification and differentiation of cortical 
progenitors. The transformed cell-type specific populations observed in our D-APV 
treated cortical progenitor cultures suggests significant roles for NMDARs in the normal 
development of the human cerebral cortex.  
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 Introduction 
 
Glutamate receptors involved in cellular excitation are of three types, AMPA, 
Kainate and NMDA, named after the synthetic agonists that activate these receptors viz., 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate, and N-methyl 
D-aspartate (NMDA), respectively (Watkins and Evans, 1981; Foster and Fagg, 1984; 
McLennan, 1984; Mayer and Westbrook, 1987). In the brain, these receptors are 
activated by their endogenous ligand glutamate. Activation of the AMPA and kainate 
receptors mediates fast excitatory postsynaptic potentials, but the NMDARs have 
functions that are highly dependent on their subunit composition (Dingledine, 1986; 
Cotman and Iversen, 1987). Physiological studies have indicated that this receptor has 
the unusual property of becoming active only on depolarization (Dingledine, 1983) due to 
a voltage-dependent block of the associated ion channel by magnesium (Mayer et al., 
1984; Nowak et al., 1984). This intriguing property of NMDARs makes it a ligand- and 
voltage-gated ion channel with wide variety of roles in development and adulthood.  
 
The availability of several potent and selective NMDAR antagonists, such as D-
APV (D-amino phosphonovalerate, Watkins and Olverman, 1987), has provided the 
necessary pharmacological tools for understanding many aspects of NMDAR action. D-
APV blocks depolarization induced by iontophoretic application of NMDA but is without 
effect on kainate and AMPA-induced depolarization (Crunelli et al., 1983; Harris et al., 
1984). It can block low-frequency synaptic transmission in the cerebral cortex (Thomson  
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et al., 1985), the induction of sustained depolarization by high-frequency 
stimulation and the propagation of epileptiform discharges in hippocampal slices (Herron 
et al., 1986). NMDAR antagonists are potent muscle relaxants (Turski et al., 1985) and 
anticonvulsants (Croucher et al., 1982; Patel et al., 1988) and can also protect neurons 
against ischemia (Simon et al., 1984; Meldrum, 1985). Important as these latter 
observations undoubtedly are, it seems unlikely that the normal function of NMDARs is 
to “lurk malevolently in the surface membrane, waiting to cause epilepsy” (Dingledine, 
1986). What, then, might be their function?  
 
The use of selective NMDAR antagonists such as D-APV offers a new avenue for 
exploring the hypothesis that NMDARs play a significant role in human cortical 
development. Specifically, it allows for the first time investigation of the molecular and 
physiological capacities of human cortical progenitor cells, such as their proliferation and 
differentiation, process that require functional NMDARs in rodent neurodevelopment. The 
hypothesis makes an important and testable prediction that D-APV should impair a subset 
of developmental processes that are critically important in corticogenesis. The following 
series of experiments will enable identification of cellular events that are dependent on 
NMDAR function in human cortical development at midgestation.  
 
Material and Methods 
 
Human Fetal Brain Tissue 
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 The same tissue characterized in Chapter 3 will be used in experiments described in this 
Chapter. 
 
Human fetal brain tissue (n = 4) between 16 gw and 19 gw (case numbers 3, 4, 5, 
7 from Table 1) free of any developmental abnormalities was obtained, handled and 
processed as described in detail in Chapter 3, strictly following regulations of the Ethics 
Committee at UConn Health. A small piece (1 cm2) of the dorsal telencephalic region was 
used to generate dissociated cell cultures (Zecevic et al. 2005; Radonjic et al., 2014).   
 
Dissociated Mixed Cell Culture and Enrichment of RGCs 
 
Establishment of dissociated mixed cell cultures and enrichment of RGCs using MACS 
were was performed as previously described in Mo et al., 2007 and Radonjic et al., 2014. 
These protocols were described in detail in Chapter 3. The enriched RGCs were plated 
on poly-D-lysine (Sigma-Aldrich) coated coverslips (12 mm) at a density of 250,000 
cells/ml and subjected to double immunocytochemistry experiments with antibodies 
against RGC markers CD15, brain lipid binding protein (BLBP) or glial fibrillary acidic 
protein (GFAP). Counting cells that co-labeled with CD15 and BLBP or CD15 and GFAP 
from total number of cells (BB+) revealed that the RGC cultures were 98% homogenous 
(Figure 16). Poly-D-lysine coated six wells (10 cm2 growth area/well) were then plated 
with 2 million cells/ml and the collected cell lysates were used for total protein and RNA  
 
 121 
 
Figure 16. (A) Timeline of experiment showing that enriched RGC cultures were studied 
for their homogeneity after 3 DIV in PM. (B) Double immunocytochemistry showing CD15 
(green) expression on BLBP+ and GFAP+ RGCs. 
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 isolation. After 3 DIV in proliferation medium (PM), the culture medium was change to 
differentiation medium (DM) devoid of growth factors and cells were allowed to 
differentiate for additional 7 DIV.  
 
Pharmacological Treatments of Cell Cultures  
 
RGCs cultures were treated for 48 h with NMDAR-specific antagonist D-APV 
(Tocris Biosciences, Bristol, UK) dissolved in PM. The EC50 for D-APV was determined 
in Chapter 3 using cell survival and proliferation assays and was determined to be ~ 0.05 
μM. These assays enabled us to decide the treatment concentrations to be used for 
further experiments, where cells were analyzed after 3 DIV in PM, and after 7 DIV in DM.  
 
Cell Survival Assay 
 
A live/dead assay (Molecular Probes, Eugene, OR, USA) was used to determine 
the effects of NMDAR blockade on cell survival, as described in detail in Chapter 3. 
Briefly, calcein-AM penetrates the living cells, and upon cleavage by intracellular 
esterases calcein fluoresces green (emission at 515 nm). In contrast, EthD-III intercalates 
with the exposed DNA of dead cells emitting red light at 620 nm. Since both Calcein and 
EthD-III can be excited at 490 nm, a simultaneous monitoring of viable and dead cells is 
possible using a fluorescence microscope.   
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Proliferation Assay 
 
Comparing the percent of proliferating cells [(Ki67+/BB+)*100] between control and 
D-APV treated cultures revealed the effect of NMDAR blockade on cell proliferation, as 
described in Chapter 3.  
Immunocytochemistry (ICC) 
 
Control and D-APV treated cells fixed in 4% paraformaldehyde were washed in 
PBS, blocked (blocking buffer: 10% BSA< 10% NGS, 0.05% Triton X-100 in PBS) for 1 h 
at RT, and incubated with primary antibodies (diluted in blocking solution; Table 5) at 4oC 
overnight. Cells were then washed, incubated with fluorophore-conjugated secondary 
antibodies for 2 h at RT, stained for nuclei using bis-benzimide (BB) for 1 min at RT, and 
coverslipped using the anti-fade reagent Fluoromount-G (Southern Biotech, Birmingham, 
AL) to preserve fluorescence.  
 
Image analysis 
 
Immunolabeled samples were visualized using an Axioscope microscope (Zeiss, 
Germany) together with Axiovision software and photographed using a digital camera. 
Imaging analysis criteria were strictly followed as described in Chapter 3.   
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 Western Blot 
 
Cell lysates were collected from control and D-APV treated cultures following the 
detailed protocol described in Chapter 3. Protein concentration was determined using the 
BCA colorimetric assay (Thermo Scientific). Samples were run, and transferred as 
described in Chapter 3. The blot was blocked with 5% milk in TBS-T, incubated with 
primary antibodies diluted in blocking buffer (Table 5) at 4oC overnight, washed with 1X 
TBS-T (10% Tween, PBS, 0.1% TritonX-100, distilled water), incubated with HRP- 
conjugated secondary antibodies (Millipore) for 2 hours at RT, washed again, and then 
incubated with SuperSignal West Dura Extended Duration Substrate (Thermo Scientific). 
The blots were imaged on ChemiDoc MP (Bio-Rad) digital imaging system, and 
densitometric analysis was performed as described in Chapter 3.  
 
Real-time polymerase chain reaction (RT-PCR) and quantitative PCR (qPCR) 
 
RNA isolation and cDNA synthesis were performed on cell lysates of control and 
D-APV treated cultures using the protocol described in Chapter 3. RNA and cDNA 
concentrations were determined using the NanoDrop technology (260/280 ratios obtained 
were between 1.93 and 2.0). cDNA was synthesized by reverse transcriptase-PCR (RT-
PCR) using the First Strand Synthesis SuperScript III kit (Invitrogen). The SYBR Green 
(Applied Biosystems, Cheshire, UK) protocol was used to analyze the expression levels  
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of many gene transcripts (Table 6) by performing quantitative PCR (qPCR) using the 
CFX96 Connect™ thermocycler (Bio-Rad). The qPCR protocol and data analysis are 
described in detail in Chapter 3.   
 
Statistics 
 
All data were expressed as mean + standard error of mean (SEM). Mean, SEM 
and p-values were calculated in Microsoft Excel. For all Western Blot and qPCR 
experiments, triplicate values were averaged across the four brains (n=4; 16-19 gw) for 
each treatment to obtain a mean value for each treatment. The means obtained from each 
brain in a treatment group were averaged to obtain a group mean. Variations were 
expressed as the mean ± standard error (SEM). One-way ANOVA followed by 
Bonferroni’s post-hoc test was used to evaluate statistical significance, defined as a p 
value <0.05.  
 
Results 
NR1 is expressed in RGC cultures  
 
We examined the expression of the NMDAR subunit NR1 in our enriched dorsal 
RGC cultures (see Methods; Figure 16). Since D-APV acts on NMDARs, it was important 
to determine if the enriched progenitor population expressed NMDARs, and to confirm 
our result on NMDAR expression in the human fetal brain cryosections (Chapter 2).  
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 Figure 17. NR1 subunit expression at mid-gestation in vitro. (A) Timeline showing that 
NR1 expression was analyzed on progenitors after 3 DIV in PM and on mature cell types  
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Furthermore, NR1 is the obligatory subunit of NMDARs (Cull-Candy et al., 2001), and it 
is known that NMDARs do not assemble and function without the NR1 subunit (Standley 
et al., 2000). Therefore, we examined the expression of the NR1 subunit in the enriched 
RGC cultures before we treated them with D-APV. We found that cultured human RGCs, 
after 3 DIV of proliferation and 7 DIV of differentiation (Figure 17A), indeed express the 
NR1 subunit gene, Grin1 (Figure 17B) and protein (Figure 17C) in all fetal brains studied 
(n=4; 16-19 gw). Thus, we conclude that at mid-gestation, the NR1 subunit is expressed 
in human cortical progenitor cells in vitroafter 7 DIV in DM; n =4. (B) qPCR and (C) 
Western blot showing NR1 gene and protein expression, respectively, mean+SEM.  
 
NMDAR blockade induces cell death and interferes with cell proliferation 
 
In order to determine the concentrations of D-APV that can be used in our in vitro 
system for future studies, we measured responses such as cell death and proliferation in 
our D-APV treated RGC cultures. The enriched RGC cultures were treated with eight 
different concentrations of D-APV for a period of 48 h (Figure 18A). The effect of D-APV 
on RGC proliferation and cell survival was measured, and these responses were plotted 
against the eight different concentrations (0 μM to 100 μM) of D-APV to obtain the 
concentration-response curves. These plots helped identify the effective concentration at 
which 50% of the cell population was affected (EC50), and thereby pinpoint the minimum 
inhibitory concentration (MIC) for D-APV in human RGC cultures. We observed that the 
concentration 0.05 μM effectively induced 50% cell death and concentration 0.01 μM  
128 
 effectively inhibited 50% of cell proliferation (Figure 18B,C), we used the following 
treatment concentrations for further experiments: 0.001 μM, 0.005 μM  and 0.01 μM of D-
APV for 48 h. The cell survival and proliferation assays also indicated that blocking 
NMDARs negatively influences processes of cell survival and proliferation. This data 
suggests that NMDARs play a significant role in basic cellular processes in human RGC 
cultures at mid-gestation. 
 
RGC specification is altered upon blocking NMDARs 
 
In order to examine the role of NMDARs in cortical progenitor specification, we 
allowed the D-APV treated RGC cultures to proliferate for 3 DIV in PM, following which 
we analyzed the expression of progenitor genes and proteins. RT-PCR revealed that after 
D-APV treatment, expression of progenitor specific genes such as Nestin expressed in 
all neural progenitors, Tbr2 expressed in intermediate progenitors, and Nkx2.1 expressed 
in interneuron progenitors, all decreased in a concentration-dependent manner, while 
expression of the astroglial gene, Gfap increased, notably with the highest D-APV 
concentration of 0.01 μM (p < 0.05; Figure 19A). Protein expression, examined in whole 
cell lysates using Western blotting, revealed that the 48 h D-APV treatment significantly 
reduced expression levels of a protein specific for the radial glia cortical progenitors. The 
Western blots showed that the two highest concentrations of D-APV – 0.005 μM and 0.01 
μM – led to a decrease in expression of the RGC specific protein BLBP, while the 
astroglial protein GFAP showed an increase in expression (Figure 19B). This was  
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 Figure 18. Concentration-response curve for in vitro D-APV treatment. (A) Timeline of the 
experiment. (B) The live/dead assay: live (green) and dead cells (red) for control and drug 
treatments. (C) Ki67+ proliferating cells (red); nuclear stain BB (blue); n =4; p < 0.05 
between DMSO and each treatment. Error bars represent mean+SEM; DMSO-Dimethyl 
sulfoxide, D-APV- D-amino phosphonovalerate.  
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 evidenced in D-APV treated RGC cultures across all four ages tested (16-19 gw). These 
observations at the protein levels were in accordance with those observed at the gene 
expression levels, and the effects of D-APV on progenitor gene and protein expression 
were found to be concentration-dependent.  
Looking at the effects of D-APV on the cell types using immunocytochemistry 
(Figure 20A), we found that the percentage of Tbr2+ intermediate progenitors, and 
Nkx2.1+ interneuron progenitors from total number of cells in the culture were significantly 
reduced with the two highest concentrations (0.005 μM and 0.01 μM), while all three 
concentrations of D-APV significantly decreased the percentage of Pax6+ RGCs (p<0.05).  
These results were in line with those observed from the qPCR and Western blotting 
experiments. Similar to the data on gene and protein expression, we found a significant 
increase in the GFAP+ astrocytic population in D-APV treated cultures (p < 0.05; Figure 
20B). 
These results indicate that specification of human cortical progenitors requires 
NMDARs, and blocking these receptors with a specific antagonist D-APV alters the of 
progenitor specification by reducing the number of progenitor subtypes (Tbr2, Nkx2.1) 
and increasing the number of GFAP+ astroglial cells, way before they are programmed to 
do so. This shortens the time period of progenitor pool expansion, reducing the number 
of progenitors available to differentiate into neurons. Further, blocking NMDARs induced 
gliogenesis in cortical RGC cultures that usually occurs after completion of neurogenesis 
in vivo. This alteration in the progenitor specification process timeline is likely to alter the 
downstream process of neurogenesis and gliogenesis.  
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Figure 19. Blocking NMDAR affects cell fate determination in vitro. (A) D-APV treatment 
decreased progenitors but increased astroglia specific gene expression in a 
concentration-dependent manner, (B) Western blot from 17 gw D-APV treated cell lysates 
showed a decrease in progenitor, but increase in astroglia protein expression in a 
concentration-dependent manner. 
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Figure 20. Blocking NMDARs with D-APV affects progenitor cell populations in vitro. (A) 
Representative images at 17 gw for immunolabeling with specific progenitor and astroglia 
markers (red), and nuclear stain: BB (blue). (B) The immunolabeling quantification 
showed a decrease in percentage of progenitor subtypes, but an increase in astroglia 
population (n=4; p < 0.05). Scale bar 15 μm. 
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Blocking NMDARs shifts differentiation of RGCs towards glia 
 
Since D-APV negatively affected RGCs and altered their specification process, we 
hypothesized that the process of progenitor cells differentiating into cortical neurons is 
also affected. In order to test our hypothesis, we added differentiation medium (DM) to 
our progenitor cell cultures for 7 DIV and then assessed their differentiation into either 
neurons or astrocytes. Gene expression analysis using qPCR showed that D-APV 
decreased expression of neuronal genes Neurogenin 1/2, Tbr1, and Gad65 in a 
concentration-dependent manner, but increased expression of astrocytic gene Gfap (p < 
0.05; Figure 21A). This finding was further supported by a decrease in the neuronal 
protein βIII tubulin, but an increase in the astrocytic protein GFAP after D-APV treatment 
(Figure 21B). To analyze the effect of D-APV treatment on specific cell-types, we 
performed immunocytochemistry using antibodies specific to neuronal proteins (Figure 
22A). We observed a significant concentration-dependent decrease in the number of cells 
labeled with neuronal markers (β-III-tubulin, Tbr1, GABA). Moreover, the D-APV 
treatment had a significantly greater effect on GABAergic interneurons depleting half their 
population, compared to the Tbr1+ glutamatergic neuronal population that decreased by 
15%. This bias suggests that blocking NMDARs during neurogenesis hampers the 
differentiation of cortical progenitor cells into GABAergic interneurons while relatively 
sparing the glutamatergic neuronal subpopulation. Once again, we found an increase in 
the number of GFAP+ astrocytes, indicating a drive towards astrocytes formation Figure 
22B).  
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Figure 21. Blocking NMDAR affects neuronal differentiation in vitro. (A) D-APV treatment 
decreased neuronal but increased astroglia specific gene expression in a concentration-
dependent manner, (B) Western blot from 17 gw D-APV treated cell lysates showed a 
decrease in neuronal, but increase in astroglia protein expression in a concentration-
dependent manner. 
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 Figure 22. Blocking NMDARs with D-APV affects progenitor populations in vitro. (A) 
Representative images at 17 gw for immunolabeling with specific neuronal and astroglia 
markers (red), and nuclear stain: BB (blue). (B) The immunolabeling quantification 
showed a decrease in percentage of neuronal subtypes, but an increase in astroglia 
population (n=4; p < 0.05). Scale bar 15 μm. 
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15 μm 
 Our results demonstrated that D-APV influenced the specification and 
differentiation of cortical RGC progenitors by depleting the number of progenitors 
available for neurogenesis. Furthermore, it caused an untimely increase in the astroglial 
population. This developmental shift in gliogenesis occurring before neurogenesis could 
be detrimental to cortical circuitry formation and function.  
 
NMDAR blockade leads to an increased activation of astrocytes 
 
It has been reported that NMDAR hypofunction triggers S100β expression activating 
cerebral astroglia in primary rat astrocyte cultures established from Wistar rats at P1-P2 
(Tramontina et al., 2006; Nardin et al., 2009). Reactive astrocytes are known to generate 
an inflammatory response that involves secretion of pro-inflammatory cytokines 
(Guillemin et al., 2001; Meyer et al., 2011). To test this possibility in our cultures, we first 
immunolabeled D-APV treated RGC cultures with S100β, a cytoplasmic marker for 
reactive astrocytes (Figure 23). 
 
The number of S100β+ cells was quantified after the 48 h of D-APV treatment to 
examine if the activation of astrocytes occurs immediately after the treatment. We found 
that 0.01 µM D-APV triggered the activation of astrocytes, as evidenced by the increased 
number of S100β+ cells in the immunocytochemistry (Figure 23). Such an increase in the 
reactive astrocyte population during development could result in a neuro-immunological 
response. 
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Figure 23. Blocking NMDARs activates astrocytes. Immunocytochemistry for S100β, a 
marker for reactive astrocytes, was performed on D-APV treated RGC cultures. The 
immunostaining reveals an increase in the number of S100β+ cells in cultures treated 
with the highest concentration of D-APV (0.01 µM; bottom) as compared to control (top). 
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 Discussion 
 
A significant feature of this study includes the exploration of NMDAR-specific 
blockade on human cortical development in cell cultures at midgestation. Major findings 
from this study demonstrate that D-APV, a NMDAR-specific antagonist, affects human 
cortical progenitors on several developmental levels. First, after D-APV treatment, the 
survival and proliferation of RGCs decreased. Second, further specification of RGCs into 
intermediate progenitors is impaired. Third, significant shifts occur in the specification and 
differentiation of human neural progenitor cells after blocking NMDARs. Fourth, D-APV 
treatment effectively gives rise to an increased number of astrocytes, as evidenced by 
the increase in number of GFAP+ cells. Upon further analysis, it was revealed that these 
astrocytes are activated as demonstrated by an increase in S100β expression, a 
cytoplasmic marker abundantly expressed in reactive astrocytes. In summation, these 
results indicate that blocking NMDARs during cortical development at midgestation, a 
time point of active neurogenesis and synaptogenesis in the human cerebral cortex, can 
change the cellular makeup, and possibly induce an immunological response, all building 
up towards impairing cortical development. 
 
D-APV reduces the progenitor pool and disrupts neurogenesis in vitro 
 
D-APV is a non-competitive antagonist of NMDARs, and is responsible for a broad 
spectrum of effects, including the regulation of NMDAR-dependent excitability and the  
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initiation of astrocyte-dependent neuro-immunological response (Davies et al., 1981, 
1982; Nargi-Aizenman and Griffin, 2001). In this study, we showed that blocking NMDARs 
with D-APV induces cell death of human cortical progenitors (RGCs, Tbr2, Nkx2.1). Our 
results are in agreement with studies in rodents (Ciani et al., 1997), and in vitro studies 
on human neural precursor cells (Suzuki et al., 2006).  
 
NMDARs are important for many events during embryonic development in rodents 
and humans (Manent et al., 2005, Suzuki et al., 2006, Toriumi et al., 2012). In vivo 
blockade of NMDARs induces apoptosis during rat cortical development ultimately 
leading death of the animal (Ikonomidou et al., 1999). In our in vitro study, we observed 
that antagonizing NMDARs with D-APV increases cell death, and decreases proliferation 
of human cortical progenitors, showing the importance of NMDARs for both survival and 
proliferation of RGCs during the second trimester of gestation. 
 
NMDARs are important for cell fate determination  
 
It is important to understand if NMDARs have differential roles in determining the 
cell fate of RGCs to generate intermediate progenitors and two subtypes of cortical 
neurons, the excitatory glutamatergic neurons (Tbr1+ cells), and GABAergic interneurons. 
To study this question, we used various transcription factors to label distinct progenitor 
populations in vitro, like in Chapter 3. In this Chapter, we have shown that a NMDAR-
dependent decrease in Nkx2.1 and Tbr2 expression resulted in a decrease of GABAergic  
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 interneurons which was more pronounced than the decrease of Tbr1+ glutamatergic 
neurons. These data suggest that a NMDAR-dependent alteration in the cortical 
progenitor pool disrupts neurogenesis and subsequently may affect the proportionate 
balance of cortical cell types and formation of the cortical circuitry. The NMDAR blockade 
induced an increase in astrocyte population, as well as an enhanced expression of S100β 
implying the beginning of a neuro-immunological response. Interestingly, astrocytic 
hypertrophy has been reported in the prefrontal cortex of patients with bipolar disorder 
(Rajkowska et al., 2001), Alzheimer Disease (Nardin et al., 2009), and Sindbis virus brain 
infection (Nargi-Aizenman and Griffin, 2001) indicating that reactive astrocytes can be a 
major component of neuropsychiatric illness.  
 
Consequences of NMDAR-blockade during human fetal neurodevelopment  
 
NMDARs have important roles in the CNS, and data over the years have implied 
the role of NMDARs in numerous processes of brain development (reviewed in Paoletti 
et al., 2013). Specifically, exposure to NMDAR antagonists and channel blockers like 
ketamine, and PCP during fetal development have long-lasting consequences for 
subsequent brain and behavioral development and might lead to structural and functional 
brain abnormalities in adult life (Iaccarino et al., 2013).  
 
The consequences of NMDAR blockade in human cortical development are not 
well recognized or understood, and therefore, our purpose in this study was to identify  
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and highlight the significance of these receptors in human cortical development. Our in 
vitro study shows that D-APV results in larger deficits in GABA+ interneurons compared 
to a Tbr1+ subpopulation of projection neurons at midgestation when upper cortical layers 
crucial for the formation of cortico-cortical connections and emergence of higher brain 
functions are formed. The preferential vulnerability of interneurons might be clinically 
relevant since hypofunction of NMDARs on cortical interneurons is well-reported and 
hypothesized to be the key element in explaining the pathophysiology of 
neurodevelopmental disorders including schizophrenia and autism spectrum disorder 
(DeFelipe, 1999; Gleeson and Walsh, 2000; Baraban and Tallent, 2004; Lewis et al., 
2005). This is the basis of the glutamate hypothesis of schizophrenia (Belforte et al., 2010; 
Nakazawa et al., 2012). Together, these changes can have a negative impact on cortical 
functions during adolescence, a stage when complex cognitive and emotion-based 
functions develop, and a time point at which schizophrenia symptoms often first manifest 
(Uhlhaas, 2011).   
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Chapter 5 
 
KYNA elicits an immune response in cultured human cortical cells  
 
Note: To evaluate whether treatment with KYNA can lead to an immune response, we 
used mixed cell cultures, and all experimental approaches are as those described for 
enriched RGCs in Chapter 3. 
 
Abstract 
 
Kynurenic acid (KYNA), an NMDAR antagonist has been hypothesized to activate 
astrocytes and elicit an immune response. Data about this mechanism, which could play 
an important role in neurodevelopmental disorders, are not available for human. To 
evaluate the neuro-immunological role of KYNA, we treated human fetal cortical mixed 
cell cultures (16-19 gw) with different concentrations of KYNA. A cell survival and 
proliferation assay determined that the EC50 for KYNA is 0.05 μM in our in vitro system. 
Treatment with three concentrations of KYNA below the EC50 (0.001 μM, 0.005 μM, 0.01 
μM) for 48 h showed a  concentration dependent increase in the number of  reactive 
astrocytes (S100β+ cells) with 40% of cells being S100β+ in the highest concentration 
(0.01 μM). Furthermore, a significant increase in the concentration of cytokine IL-6 in cell 
media supernatants was demonstrated after 24 and 48 h of KYNA treatment. Moreover, 
higher levels of a cell signaling molecule, phosphorylated STAT3 (pSTAT3) indicated 
activation of the Jak-STAT pathway. pSTAT3 induces transcription of astrocytic gene 
Gfap, and the observed increase in levels of pSTAT3 are indicative of increased 
gliogenesis. Taken together, these results are in line with previous studies in animals and 
suggest that elevated levels of KYNA can trigger an immune response and activate 
downstream transcription machinery within 48 h in human fetal cortical mixed cell 
cultures.   
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 Introduction 
 
Glutamate is firmly established as the major excitatory neurotransmitter in the 
mammalian brain and is actively involved in most aspects of neurophysiology (Curtis and 
Johnson, 1974; Mitchell et al., 1994; Watkins, 2000). Moreover, glutamatergic 
impairments are associated with a wide variety of dysfunctional states, and both hypo- 
and hyper-function of glutamate have been plausibly linked to the pathophysiology of 
neurological and psychiatric diseases (Schoepp and Conn, 1993; Belforte et al., 2010; 
Plitman et al., 2014). Kynurenines are metabolites of the kynurenine pathway, the major 
catabolic route of the essential amino acid tryptophan, that influence glutamatergic activity 
in several distinct ways (Moroni et al., 1988; Pocivavsek et al., 2011; Liu et al., 2014). 
This includes direct effects of kynurenines on ionotropic and metabotropic glutamate 
receptors or vesicular glutamate transport (Setiadi et al., 2015), and indirect effects like 
upregulating expression of non-α7 nicotinic acetylcholine receptors (nAChR), which are 
initiated by actions at various other recognition sites like the α7nAChR (Hilmas et al., 
2001). In addition, some KP metabolites affect glutamatergic functions by generating or 
scavenging highly reactive free radicals (Giles et al., 2003; Robert et al., 2014). Our study 
summarizes and discusses the implications of elevated KYNA levels in human cortical 
development through the use of human primary mixed cortical cultures. 
 
Over the past years, there has been increasing evidence that 
inflammations/infections might be the causal factors, underlying the pathophysiology of  
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schizophrenia and bipolar disorder. Indeed, epidemiological studies suggest that early-
life infections are associated with the development of neuropsychiatric disorders later in 
life (review in Selemon and Zecevic, 2015). In particular, earl-life exposure to herpes 
simplex virus type 2, cytomegalovirus, rubella and influenza viruses, as well as to 
Toxoplasma gondii, is associated with an increased risk of developing schizophrenia 
(Karlsson, 2003; Yolken and Torrey, 2008). Furthermore, epidemiological studies show 
that children whose mothers were seropositive for a number of different pathogens during 
pregnancy have increased risk of developing schizophrenia or psychosis (Canetta and 
Brown, 2012). Several epidemiological studies have also investigated cytokines, small 
communicative proteins of the immune system. A recent meta-analysis study found 
significant increase in serum levels of IL-1β, sIL-2R, IL-6 and TNF-α in first episode of 
psychosis, suggesting that the increase in these cytokines is unrelated to anti-psychotic 
treatment (Upthegrove et al., 2014). With regard to central levels of cytokines, the 
increased cerebrospinal fluid levels of IL-6 (Garver et al., 2003; Sasayama et al., 2013; 
Schwieler et al., 2015) and IL-1β (Söderlund et al., 2009) were demonstrated in 
schizophrenia. Cytokines, beside their classical immune actions, play multiple non-
inflammatory and non-immune roles in development, plasticity and function (Estes and 
McAllister, 2014) and interestingly, both IL-1β and IL-6 are able to induce the kynurenine 
pathway (Urata et al., 2014; Sellgren et al., 2015; Schwieler et al., 2015). The neuro-
inflammatory pathology in schizophrenia involves abnormal astrocyte functions as seen 
by the increased levels of S100β in serum and/or cerebrospinal fluid. S100β is a protein 
involved in a variety of neuronal and glial signaling mechanisms, which is primarily  
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 produced by activated astrocytes, so elevated central levels of this protein likely reflect 
astrocyte over-activation (Rothermundt et al., 2009). An increase in cytosolic calcium 
concentration is necessary for IL-6 secretion from reactive astrocytes (Codeluppi et al., 
2014). Furthermore, the Janus kinase/signal transducer and activator of transcription 3 
(JAK/STAT3) pathway is associated with the production of reactive astrocytes (Haim et 
al., 2015; Lee et al., 2016) downstream of IL-6 signaling (Campbell et al., 2014). All these 
compelling theories, and observations are however, obtained from studies in rodents. We, 
therefore, set forth to examine the effects of elevated levels of KYNA, and the KYNA-
mediated inflammatory response and signaling pathways in human cortical mixed cell 
cultures. 
 
Primary brain and neuron cultures are used for neurobiological, 
neurodevelopmental, pharmacological and toxicological studies of various 
neuropsychiatric disorders. To date, the majority of the neuron cultures are prepared from 
embryonic (Bailey et al., 2011; Vicario-Abejon, 2004) or adult rodent brains (Brewer and 
Torricelli, 2007; Ray et al., 2009). However, human neurodevelopmental disorders such 
as schizophrenia and autism need to be studied in human tissue because these diseases 
are known to occur only in humans, and it is well-reported that the cerebral cortex exhibits 
species-specific differences (refer to Chapter 3). Our laboratory has previously developed 
and characterized primary neural cultures derived from the human fetal cerebral cortex 
(see Methods). In this study we established primary human mixed cell cultures from fetal 
brains between 16 gw and 19 gw (the entire gestational period in humans is 40 weeks  
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long). Development of the human cerebral cortex begins in the first trimester (7-8 gw) and 
continues through the second trimester and beyond (Bystron et al., 2008, Malik et al., 
2013). Since we used brain tissue from fetuses during the second trimester of gestation, 
the majority of the cells are neural progenitors and the neurons are still young and 
immature. At the initial phase of the cultures (3 DIV), the cells co-express markers of both 
neuronal and glial origin, consistent with their immature nature. After 10 DIV, mature 
neurons and glia are also present (Howard et al., 2006). This in vitro system of human 
cortical mixed cells closely represents the in vivo scenario by containing all the cell types 
present in the fetal brain, and is therefore, better than the enriched radial glia cultures 
used in Chapter 3 and 4 for evaluating the effects of KYNA on various cell types, and to 
identify the mechanism through which KYNA exerts these effects in human cortical 
development. 
 
Materials and Methods 
 
Human Fetal Brain Tissue 
The same tissue characterized in Chapter 3 will be used in experiments described in this 
Chapter. 
 
Human fetal brain tissue (n = 4), free of any developmental abnormalities,  at 16 
to 19 gw was obtained with the approval of the Ethics Committees and with written 
informed consent, from Human Developmental Biology Resource (Newcastle University,  
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 Newcastle upon Tyne, England) and the Tissue Repository of The Albert Einstein College 
of Medicine (Bronx, NY, USA). Handling of the human material was done with special 
care following all necessary requirements and regulations set by the Institutional Ethics 
Committees. The age of the tissue was determined by the following criteria: crown-rump 
length, weeks after ovulation, and anatomical landmarks. The tissue was transported on 
ice in Hank’s Balanced Salt Solution (HBSS; Life Technologies, Grand Island, NY, USA) 
from the aforementioned brain repositories to the lab. A small piece (1 cm2) of the dorsal 
telencephalic region was used to generate dissociated cell cultures (Zecevic et al. 2005; 
Radonjic et al., 2014).   
 
Dissociated Mixed Cell Culture and Enrichment of RGCs 
Cell cultures were established exactly in the same way as stated in Chapter 3. 
 
A previously published protocol (Mo et al., 2007) was used to establish dissociated 
mixed cell cultures. As briefly described here, the isolated tissue was dissociated 
mechanically and enzymatically at 37°C for 30 min with 0.025% trypsin (Gibco, Beverly, 
MA, USA), followed by addition of DNase (Sigma-Aldrich, St Louis, MO, USA; 2 mg/mL), 
washing with HBSS (Life Technologies) and suspension in proliferation medium (PM; 
Figure 34A). The PM consisted of DMEM/F12 (Life Technologies) supplemented with 10 
ng/mL of basic fibroblast growth factor (bFGF, Peprotech, Rocky Hill, NJ, USA), 10 ng/mL 
of epidermal growth factor (EGF, Millipore, Billerica, MA, USA), and B27 (Life 
Technologies). The dissociated mixed cells were plated on T-75 flasks coated with poly- 
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D-lysine (Sigma-Aldrich), and were allowed to proliferate in PM containing Rock inhibitor 
(1 μM) till 80% confluency was reached (five days after plating). The Rock inhibitor aids 
in the adherence and spread of cellular processes in 2D cultures. Cultures are then 
trypsinized (0.05% Trypsin-EDTA; Life technologies, Billerica, MA, USA), concentrated, 
and the cell density is calculated using a hemocytometer. Cells were plated on poly-D-
lysine coated coverslips (12 mm) at a density of 250,000 cells/ml and on poly-D-lysine 
coated six wells (10 cm2 growth area/well) at a density of 2 million cells/ml.  After 3 DIV 
in PM, the culture medium was changed to differentiation medium (DM) devoid of growth 
factors and cells were allowed to differentiate for 7 DIV. Cells on coverslips were used for 
characterization of the cultures using immunocytochemistry, and for studying the effects 
of KYNA on cell-fate specification. Cell lysates were collected for total protein and RNA 
isolation to study the effect of KYNA on neuronal differentiation and astrogliogenesis. 
KYNA treated cells were also used for determining secreted levels of IL-6 via sandwich 
ELISA, and to examine levels of phosphorylated STAT (pSTAT) by SDS-PAGE.   
 
Pharmacological Treatments of Cell Cultures  
 
Mixed cell cultures were treated with eight different concentrations (0.001 μM to 
100.0 μM) of KYNA for 48 h, and concentration-response curves were first plotted to 
identify the minimum inhibitory concentration (MIC) of KYNA in this in vitro system. 
Responses measured were cell survival and cell proliferation. KYNA was dissolved in 
DMSO, and therefore, two sets of controls were maintained: 1) RGCs grown only in PM,  
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 2) RGCs grown in PM containing DMSO. In all analyzed experiments there was no 
difference between control PM and PM+DMSO, hence PM+DMSO results were 
represented in graphs as the control. The effective concentration at which 50% of the cell 
population was affected (EC50) was determined in both cell survival, and proliferation 
assays to decide the treatment concentrations to be used for further experiments, where 
cells were analyzed after 3 DIV in PM, and after 7 DIV in DM. We previously established 
that the obligatory NMDAR subunit NR1 is expressed from 10 gw – 24 gw in the human 
fetal telencephalon, and is present in progenitor, neuronal and astroglial populations in 
vitro. 
 
Cell Survival Assay 
A live/dead assay (Molecular Probes, Eugene, OR, USA) was performed after 48 
h of KYNA treatment to assess its effect on cell viability. The cell-permeant molecule 
calcein acetoxymethyl detects live cells that fluoresce green. Dead cells take up the DNA-
binding dye ethidium homodimer and fluoresce red.  
 
Proliferation Assay 
At the end of the 48 h KYNA treatment period, cells were fixed and immunostained 
with anti-Ki67 antibody. Ki67 is a mitotic marker indicative of cell proliferation. The 
percentage of Ki67+ cells was determined from the total number of cells marked with the 
nuclear stain bisbenzimide (BB). 
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Immunocytochemistry (ICC) 
 
Cells growing in vitro on coverslips were fixed with 4% paraformaldehyde in PBS, 
washed with PBS (phosphate buffer saline), blocked (0.2% bovine serum albumin (BSA), 
0.01 % Triton X-100, PBS) for 1 h at RT, and incubated with primary antibodies diluted in 
blocking buffer (Table 5, Chapter 3) at 4oC overnight. The following day, secondary 
antibodies conjugated to Alexa Fluor 488, and 555 (Invitrogen) were applied for 2 h at 
RT, followed by the nuclear stain BB for 1 min. All immunostained coverslips were 
mounted using the anti-fade reagent Fluoromount-G (Southern Biotech, Birmingham, AL, 
USA) to preserve the fluorescence.  
 
Image analysis   
 
The method described in Chapter 3 was used. In short, immunolabeled samples 
were visualized using an Axioscope microscope (Zeiss, Germany) together with 
Axiovision software and photographed using a digital camera. The images were 
assembled in Adobe Photoshop (v. 7.0), with consistent quality adjustments for contrast, 
brightness and color balance. Immunolabeled cells from 10 predesignated adjacent 
optical fields and from four different human samples per experiment were analyzed using 
Adobe Photoshop (v. 7.0).  
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 Western Blot (WB) 
 
Cells were homogenized in lysis buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 
1% NP-40, 1 mM phenylmethylsulfonyl fluoride, Sigma Aldrich, protease and 
phosphatase inhibitors (PMSF (1 mM), NaF (5 mM), Na-orthovanadate (1 mM), PIC (1 
mM; Thermo Scientific)) on ice for 30 min, centrifuged at 14,000 × g for 15 min at 4oC, 
and the supernatants were collected. Protein concentration was determined using the 
BCA colorimetric assay (Thermo Scientific). Proteins were separated on a 4-15% gradient 
polyacrylamide gel (Bio-Rad, Portland. ME, USA) at 110 volts for 75 min, and were 
transferred onto the polyvinylidene fluoride (PVDF) membrane at 100 volts for 60 min. 
After blocking with 5% milk in TBS-T, the membrane (blot) was incubated with primary 
antibodies diluted in blocking buffer (Table 5, Chapter 3) at 4oC overnight. The blot was 
washed with 1X TBS-T (10% Tween, PBS, 0.1% TritonX-100, distilled water), and 
incubated with HRP- conjugated secondary antibodies (Millipore) for 2 hours at RT. After 
three washes, blots were incubated with SuperSignal West Dura Extended Duration 
Substrate (Thermo Scientific), and were imaged on ChemiDoc MP (Bio-Rad) digital 
imaging system, taking images that were not saturated. Protein levels were quantified by 
densitometric analysis and normalized to GAPDH levels, determined using an anti-
GAPDH antibody (1:5000).  
 
Sandwich Enzyme Linked Immunosorbent Assay (Sandwich ELISA) 
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The eBioscience High Sensitivity human anti-IL6 ELISA (San Diego, CA) kit was 
used for the sandwich ELISA experiments on dissociated mixed cell cultures prepared 
from four fetal brains (16-19gw). The assay was performed according to manufacturer’s 
instructions, using samples that were diluted 1:2. We used Origin to plot the standard 
curve and analyze concentrations of IL-6. Graphs were plotted in Excel. 
 
Statistical methods  
 
All data were expressed as mean + standard error of mean (SEM). Mean, SEM 
and p-values were calculated in Microsoft Excel. For all Western Blot and qPCR 
experiments, triplicate values were averaged across the four brains (n=4; 16-19 gw) for  
each treatment to obtain a mean value for each treatment. The means obtained from each 
brain in a treatment group were averaged to obtain a group mean. Variations were 
expressed as the mean ± standard error (SEM). One-way ANOVA followed by 
Bonferroni’s post-hoc test was used to evaluate statistical significance, defined as a p 
value <0.05.  
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 Figure 24. Human cortical mixed cell cultures contain GFAP+ astroglia, BLBP+ RGCS, 
βIII tubulin+ neurons, and GABA+ interneurons, cell types that represent major cellular 
populations in the developing human cerebral cortex at mid-gestation. Representative 
images are taken from 17 gw mixed cell cultures growing for 5 DIV in PM.  
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Results 
 
Human fetal mixed cells consist of progenitors, neurons and astroglia  
 
Using the dissociated mixed cell cultures (see Methods), we explored whether the 
isolated cells express the major cell-type specific protein markers. Indeed, human fetal 
cortical cultures from all fetal brains studied (n=4, 16-19 gw) after 5 DIV in PM express 
BLBP, a marker for RGCs, GFAP, a marker for astroglia, βIII tubulin, a marker for 
neurons, and GABA, a marker for the interneurons (Figure 24). Further, to determine if 
these cell types express the NR1 subunit of the NMDAR after 3 DIV in PM, we used 
double-immunolabeling with anti-NR1 antibody and found that RGCs, labeled with BLBP, 
intermediate progenitors labeled with Tbr2, a subpopulation of interneuron progenitors 
labeled with Nkx2.1, all express the NR1 subunit. After 7 DIV of differentiation 
(differentiation always involves incubating cells in differentiation medium), the newly 
generated neurons labeled with βIII tubulin, or with Tbr1 and GABA, markers of 
glutamatergic and cortical interneurons, respectively, expressed NR1 (Figure 25). In 
humans, GFAP is a marker of both RGCs and differentiated astrocytes, and both cell 
types express NR1 subunit. Thus, based on these co-labeling experiments, we conclude 
that at midgestation all the major cortical cell types express the NR1 subunit of NMDARs.  
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 Figure 25. Double immunolabeling of mixed cell cultures after 3 DIV in PM indicate that 
GFAP+ astroglia and BLBP+ RGCs (red) express the obligatory NR1 subunit (green). 
Furthermore, NR1 expression is retained after 7 DIV of differentiation and is expressed 
on βIII tubulin+ neurons and GABA+ interneurons (red). Co-labeled cells are yellow. 
Representative images are taken from 17 gw mixed cell cultures.  
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Figure 26. Representative images of the live/dead assay: live (green) and dead cells (red) 
for control (DMSO) and drug treatment (left). Graph shows that the cell death increases 
in concentration- dependent manner after KYNA treatment (right). n = 4; p<0.05; Error 
bars represent mean+SEM.  
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Figure 27. Representative images of the proliferation assay: proliferating cells (red); 
nuclear stain BB (blue) for control and drug treatments (left). Graph on the right shows  
that KYNA induced a concentration-dependent decrease in cell proliferation as compared 
to the control (DMSO). n = 4; p<0.05; Error bars represent mean+SEM.  
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KYNA was equally toxic for human mixed cells cultures as for RGC cultures  
 
Next, we examined the effects of KYNA on survival and proliferation of human 
mixed cells, in a similar way that was done for enriched RGCs (Chapter 3). Previously, in 
enriched RGC cultures, it was determined, using a cell survival assay that the EC50 for 
KYNA was around 0.05 μM. Three concentrations below the EC50, 0.001 μM, 0.005 μM 
and 0.01 μM were chosen for experiments in mixed cell cultures. Moreover, the effects of 
KYNA on cell proliferation and cell death were due to its higher affinity for NMDARs as 
compared to nAChRs, as evidenced by the shift in the dose-response curve to the left for 
the NMDAR-specific antagonist D-APV when compared to the response curves for AChR-
specific antagonist TBC, in the enriched RGC cultures (Figure 12). Response curves for 
mixed cell cultures treated with KYNA were first plotted 48 h after the treatment with three 
concentrations of KYNA mentioned above. The effects of KYNA on cortical cell survival 
and proliferation were measured at the end of 48 h. We observed that the highest 
concentration of KYNA, 0.01 μM, induced a 30% cell death compared to control (Figure 
26), similar to the effect of KYNA treatment in RGC cultures. Moreover, this effect on cell 
death was concentration-dependent. With regards to cell proliferation, KYNA decreased 
cell proliferation in a concentration-dependent manner, much as it was observed with 
enriched RGC cultures. In mixed cell cultures, only 50% of cells were proliferating with 
treatment with the highest concentration of KYNA, 0.01 μM (Figure 27). 
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 KYNA treatment increased the number of reactive astrocytes  
 
It has been previously reported that mixed cell cultures established from human 
fetal cortices contain a much higher number of GFAP+ astroglia than do the enriched RGC 
cultures (Mo et al., 2007). Keeping this in mind, we hypothesized that treatment with 
KYNA in mixed cell cultures should show a much higher increase in the number of 
reactive astrocytes than those observed in enriched RGC cultures. It is also fairly well 
established, through rodent studies, that KYNA triggers activation of astrocytes and 
generates an inflammatory response that involves secretion of pro-inflammatory 
cytokines (Guillemin et al., 2001; Meyer et al., 2011). 
 
Quantifying the number of S100β+ cells from the total number of cells in mixed cell 
cultures after the 48 h KYNA treatment, revealed that all three concentration of KYNA 
induced a significant increase in the number of S100β+ cells compared to control. 
Moreover, the highest concentration of KYNA, 0.01 μM, triggered an approximate 10 
times higher increase in the number of S100β+ cells, reaching almost 50% in 0.01 μM 
KYNA and lingering at 0.5% in control conditions (p<0.05; Figure 28). 
 
KYNA elicits an inflammatory response 
 
Reactive astrocytes are a well-known source of pro-inflammatory cytokines, one 
of which is Il-6, a primary cytokine released in inflammatory responses (Guillemin et al;  
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Figure 28. Immunocytochemistry for S100β (green), a marker for reactive astrocytes, in 
KYNA treated mixed cell cultures (left). Graph to the right shows that the number of S100+ 
cells in the control (DMSO) is very small (0.2%) and increases in cultures treated with the 
highest concentration of KYNA (0.01 µM) to almost 40% of all cells. 
 
 
 
 
 
 
 
 
 
 
 
 
166 
S100β/BB 
  
Figure 29. Sandwich ELISA for human IL-6 in cell media supernatant from KYNA treated 
mix cells cultures at 24 h and 48 h. The two highest concentrations of KYNA 0.005 μM 
and 0.01 μM significantly increased the levels of secreted IL-6 compared to control 
(p<0.05; n=4). Error bars represent mean+SEM. 
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2001; Islam et al., 2009). Using sandwich ELISA, we examined the concentration of IL-6 
in the cell culture supernatant media obtained from KYNA treated mixed cell cultures at 
two time points, 24 h and 48 h, immediately after the KYNA treatment. IL-6 levels increase 
above normal within the first 24 h of an immune response (Garver et al., 2003). Therefore, 
we chose to measure IL-6 levels after both these treatment time points (24 and 48 h). We 
observed a significant concentration-dependent increase in the levels of IL-6 in KYNA 
treated mixed cell cultures, at both time points. (Figure 29). After 24 h, the amount of IL-
6 secreted in the cell media supernatant increased, but significance was achieved only 
for the two highest concentrations 0.005 μM, and 0.01 μM of KYNA (p < 0.05), as 
compared to DMSO (control). After 48 h, the concentration of IL-6 showed significant 
increases in mixed cells treated with all three concentrations, 0.001 μM, 0.005 μM and 
0.01 μM, of KYNA compared to control (p < 0.05). Previous studies with human subjects 
have reported that the levels of IL-6 in the cerebrospinal fluid in normal patients is ~1 
pg/ml, while their age and sex matched schizophrenic counterparts show levels closer to 
4 pg/ml of IL-6 (Garver et al., 2003; Schwieler et al., 2015). Taking these small levels of 
IL-6 into consideration, our in vitro IL-6 levels measured in KYNA treated mixed cell 
cultures demonstrate a potentially significant increase in this pro-inflammatory primary 
cytokine (Figure 29), after 24 h and 48 h of KYNA treatment. 
 
Jak-STAT cell signaling pathway is activated by KYNA  
 
We observed that KYNA induced the secretion of the pro-inflammatory cytokine  
168 
  
Figure 30. Western blotting for pSTAT3 on cell lysates collected from KYNA treated mixed 
cell cultures (left). Graph to the right shows that the expression levels of pSTAT3 
increased compared to control (DMSO);  n=4; p<0.05; Error bars represent mean+SEM.  
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IL-6 in human fetal mixed cell cultures, in agreement to similar observations made in 
human fetal astrocytic cultures (Guillemin et al., 2001). Binding of IL-6 to its receptor IL-
6R triggers the auto-phosphorylation of the downstream Jak, which then phosphorylates 
STAT. Two phosphorylated STAT molecules come together to dimerize and enter the 
nucleus where they promote the transcription of specific genes. One of the STATs called 
STAT3 is known to induce transcription of the astrocytic gene Gfap. Based on the 
previous literature, and our finding of elevated IL-6 levels in KYNA treated cultures, we 
determined the levels of phosphorylated STAT (pSTAT) (normalized against GAPDH), 
the active form that brings about gene transcription, using Western blotting. We observed 
that expression levels of pSTAT increased in mixed cells treated with the highest 
concentration (0.01M)  of KYNA, as compared to control (Figure 30). This result 
suggests that with increasing concentrations of KYNA, the production of IL-6 increases, 
which activates the Jak-STAT cell signaling pathway known to initiate gene expression of 
Gfap. Notably, even though the concentrations of IL-6 obtained from all three KYNA 
concentrations is nearly the same, the amount of pSTAT is significantly higher only in the 
highest concentration of KYNA. This could be due to the fact that reactive astrocytes can 
secrete other pro-inflammatory cytokines like IL-1β, and may be the highest concentration 
of KYNA elicits a huge secretion of both IL-6 and IL-1β, enough for it to significantly trigger 
phosphorylation of STAT3.  
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 Discussion 
 
In the present study, we explored the effects of KYNA on mixed cortical cell 
cultures derived from the human fetal telencephalic tissue at mid-gestation from 16 gw to 
19 gw (n=4) Species-specific differences in cortical development between rodents and 
humans calls for studying important biological events in tissue or cell cultures established 
from human brains. Many continuous cell lines, such as human neuroblastoma or rat 
pheochromocytoma (PC12), are used as surrogate models for mature neurons by 
stimulating neuronal-type differentiation of the culture. However, these cancer cells may 
behave differently than CNS neurons. Recently, major emphasis has been given to 
differentiate human neurons from induced pluripotent stem cells (iPSC). This method is 
very promising, but the iPSCs are artificially transduced with several transcription factors, 
that can affect the results. Another approach is to prepare neuron cultures from the fetus 
of nonhuman primates (Geiger, 1958; Negishi et al., 2003).  
 
Three major findings from this study demonstrate that KYNA significantly induces 
a neuro-immunological response. First, after KYNA treatment, the number of S100β+ 
reactive astrocytes increases. Second, treatment with KYNA increased levels of IL-6 
secreted from mixed cell cultures, successfully initiating an inflammatory response. Third, 
KYNA exposure triggered activation of cytokine responsive Jak-STAT signaling pathway 
that in turn could enhance astrogliogenesis. In sum, these results indicate that altered  
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levels of KYNA during the second trimester of gestation in humans, as can result from 
maternal infections and immune activation, may elicit inflammatory responses that can 
have profound effects on cortical development. 
 
KYNA disrupts cortical cells survival and proliferation in vitro 
 
KYNA, a product of the kynurenine pathway of tryptophan degradation, and the 
only known endogenous antagonist of the NMDAR in vivo, is responsible for a broad 
spectrum of effects, including the endogenous regulation of neuronal excitability and the 
initiation of immune tolerance (Kessler et al., 1989; Wang et al., 2006). NMDARs are 
important for progenitor proliferation, differentiation and neuronal migration during 
embryonic development in rodents (Manent et al., 2005, Suzuki et al., 2006, Toriumi et 
al., 2012). Blockade of NMDARs during rat cortical development (Ikonomidou et al., 
1999), and in human RGC cultures (Chapter 4) induces cell death, reduces progenitor 
proliferation and induces astrocyte hypertrophy. Antagonizing NMDARs with its 
endogenous antagonist KYNA, in vitro, also exhibits similar effects – an increase in cell 
death, a decrease in cell proliferation, and an increase in gliogenesis, showing the 
importance of maintaining the balance between serum tryptophan, and degradation of 
tryptophan to metabolites of the kynurenine pathway, during the second trimester of 
gestation in humans.  
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 KYNA elicits a pro-inflammatory response in cortical mixed cultures  
 
The KYNA-mediated NMDAR blockade favored astrocyte generation, and in 
addition induced the activation of resting astrocytes in both RGC cultures (Chapter 3) and 
mixed cell cultures. The morphology of S100β+ cells changed, and their number 
increased, implying a pro-inflammatory response, and such astrocytic hypertrophy is well-
reported in post-mortem studies on brains of schizophrenia patients (Rajkowska et al., 
2001). Increased cerebrospinal fluid levels of pro-inflammatory cytokines such as IL-1β 
and IL-6 (Garver et al., 2003; Söderlund et al., 2009) as well as up-regulated 
cyclooxygenase (COX) expression (Das and Khan, 1998) have also been noted in 
schizophrenic patients, providing additional support for the hypothesis of activated central 
inflammatory responses in affected individuals. Consistent with this impression, Müller et 
al. 1997a demonstrated that the levels of the soluble IL-6 receptor (sIL-6R) are increased 
in the CSF of schizophrenic patients. In contrast to other soluble cytokine receptors such 
is sIL-1RA or sIL-2R, sIL-6R does not inhibit IL-6 signaling, but instead enhances IL-6 
functions by acting as an agonist in combination with IL-6 (Knüpfer and Preiss, 2008). 
Taken together, there seems to be a relative shift towards enhanced pro- inflammatory 
activity in the CNS of schizophrenic patients.  
 
Here, we showed increased numbers of reactive astrocytes in our mixed cell 
cultures, and further observed an increase in the concentration of IL-6 secreted from  
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KYNA treated cultures. Such observations are in corroboration from previous studies that 
support a pro-inflammatory hypothesis in the developmental pathophysiology of certain 
neuropsychiatric diseases including schizophrenia (Meyer et al., 2011).  
 
Consequences of elevated KYNA levels during fetal neurodevelopment  
 
The cortex is richly endowed from an early age in two key receptor targets of 
KYNA, the NMDARs and nAChRs (Ben-Ari et al., 1997; Dwyer et al., 2009). In that regard, 
a range of studies suggest that dysfunctional neurotransmission at these receptors from 
early neurodevelopment may be causally related to CNS abnormalities in a variety of 
disorders, including schizophrenia, autism-spectrum disorder, and attention deficit 
hyperactivity disorder (ADHD) (Martin and Freedman, 2007; Young et al., 2007; Deutsch 
et al., 2011; Timofeeva and Levin, 2011; Chang et al., 2014).  
 
Glutamate receptors play an essential role in brain development and particularly 
the NMDARs. NMDARs have been implicated in modulating neuronal migration, synapse 
formation (Udin and Grant, 1999; Dikranian et al., 2001), neurite outgrowth and the 
formation of spines (Ultanir et al., 2007), and other factors that contribute to neuronal 
plasticity that rapidly occurs during neurodevelopment (Drian et al., 2001; du Bois and 
Huang, 2007) in rodents. The significance of NMDAR malfunction developmentally has 
been studied using agents to directly block the receptors in rodents (Dikranian et al., 2001;  
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 Ikonomidou et al., 1999), and humans (Chapter 3). Structural and behavioral 
abnormalities that occur as a result of blocking these receptors are relevant for the study 
of various neuropsychiatric disorders (du Bois and Huang, 2007; Lindahl et al., 2008). 
 
KYNA concentrations in the developing brain fluctuate in response to 
environmental stimuli, such as maternal infection, maternal stress or an insult such as 
hypoxia. Maternal exposure to infection or stressful conditions adversely affect brain 
development and increases the risk for the offspring to develop psychiatric symptoms 
(Brown and Patterson, 2011; Fineberg and Ellman, 2013). In line with this notion, in 
rodents, both immune activation and stress during pregnancy cause rapid elevations of 
KYNA in the fetal brain (Notarangelo and Schwarcz, 2014; Notarangelo et al., 2015); 
however, the impact of these insults on long-lasting changes of KYNA in the offspring are 
still under investigation. 
 
Despite the breadth of literature on the importance of NMDARs in 
neurodevelopment, not much is known about the regulation of their function during 
development. KYNA may contribute to the regulation of these receptors developmentally 
and in return influence cortical maturation. In that regard, a number of studies have 
modeled an increase in KYNA concentrations during different stages of pre- and postnatal 
development in rodents, as maturation of the brain is a dynamic process that begins 
embryonically and continues into young adulthood. Several of these approaches have  
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found that neurodevelopment is quite susceptible to alterations in KYNA concentrations 
and studies have focused on molecular and behavioral phenotypes in adulthood after 
manipulations during various developmental periods.  
 
In our study, we used human cortical mixed cells isolated at midgestation (16-19 
gw), an important period of active neurogenesis when upper cortical layers are formed 
(Hill and Walsh, 2005), to study the effects of elevated levels of KYNA in human cortical 
development. As these layers are crucial for formation of cortico-cortical connections and 
subsequently for emergence of higher brain functions, interference with NMDAR functions 
at this developmentally sensitive period may lead to widespread effect on formation of the 
cortical circuitry, and negatively influence cortical functional maturation in adulthood 
(Uhlhaas, 2011).   
 
KYNA treatment activates the Jak-STAT pathway 
 
With respect to the potential developmental pathways involved, KYNA has been 
shown to elicit a pro-inflammatory response that can activate the JAK-STAT pathway in 
mice (Schwarz et al. 2001, Holtze et al. 2011; Erhardt et al, 2012). This would result in 
cytokine-receptor interactions and could interfere with the normal specification of cortical 
progenitors at midgestation. When IL-6R dimerizes upon binding with IL-6, the tyrosine 
residues on Jak get autophosphorylated, and trigger the activation of the Jak-STAT 
signaling pathway. STATs possess the phosphotyrosine-binding Src-homology 2  
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 domains that have a high affinity for the Jak-phosphorylated tyrosine residues. Binding of 
STATs to these phosphorylated tyrosine residues further leads to dimerization of the 
STAT molecules. STATs are of three types, STAT1, STAT2 or STAT3, and upon 
phosphorylation these can form either hetero- or homo- dimers. The STAT hetero-or 
homo-dimers get recruited to the nucleus, and in embryonic rat coritcal cultures STATs 
activate transcription of one of their target genes, Gfap. 
 
We showed an increase in expression levels of pSTAT3, and this result is 
concurrent with current literature that reports the activation of Jak-STAT pathway 
downstream of KYNA exposure in rodents. Furthermore, these results provide helpful 
insight into understanding the cell signaling pathways possibly involved downstream of 
KYNA’s binding to its target receptors such as NMDARs.  
 
In conclusion, our study extends previous findings on the effects of KYNA in 
neurodevelopment. Our study enables the identification of the novel targets like KYNA or 
pSTAT3 in the therapy of pathological conditions such as schizophrenia where KYNA 
levels are elevated.  
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Chapter 6 
 
Discussion and Future Directions 
Discussion 
NMDARs distribution and their role in various physiological processes in the brain 
are very well studied in animal models, but are sparse with regards to human cortical 
development (Suzuki et al., 2006; Jantzie et al., 2015). These studies are, however, 
necessary to better understand normal cortical development in humans, because the 
human fetal brain consists of a large and diverse set of progenitors, some of which do not 
exist in rodents, and NMDARs, (as we have seen in Chapters 2, 3 and 4) are present in 
the human fetal brain and do play an important role in the specification of human cortical 
progenitors and neuronal differentiation. Moreover, it is necessary to study NMDARs in 
human cortical tissue because environmental insults that can compromise NMDAR 
function, and interfere with cortical progenitors can lay down the etiological basis of 
neurodevelopmental disorders like schizophrenia and autism that are known to occur only 
in humans. We studied a collection of fetal brains around midgestation using a variety of 
techniques to answer these questions: 
1) Are NMDARs present in the fetal cerebral cortex? 
2) When and where are they localized, and what is their subunit composition? 
3) Which cell types express the obligatory NR1 subunit, and NR2A and NR2B 
subunits? 
4) What is the role of NMDARs in human corticogenesis? 
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 In our study, questions related to NMDARs distribution were answered by 
immunolabeling of the cryosections through the cerebral hemisphere using antibodies to 
NMDAR subunits and cell-type specific markers (for example Pax6, GFAP, β-III-tubulin). 
Because there are relatively big individual variations between human samples, we tried 
to increase the number of studied cases and to group them by age. In addition, wherever 
possible we applied a variety of methods, such as in situ hybridization, Western blot and 
qPCR on each sample to obtain a more complete picture of NMDARs distribution in the 
human fetal cortex.  
 
We demonstrated that the NR1, NR2A and NR2B subunits are expressed in all 
progenitor and neuronal populations, as well as in astrocytes. Each cell population 
occupies a specific location along the telencephalic wall, with progenitors localized in the 
proliferative VZ/SVZ layers, migrating neurons in the transient intermediate zone (IZ) and 
subplate (SP) layers, and neurons that have reached their final location in the cortical 
plate (CP) layer. The immunoreactivity for the NMDAR subunits had a transverse pattern 
across the VZ and SVZ, suggestive of the expression of NMDAR subunits along efferent 
and afferent fibers/processes, as expression of NMDARs was reported at both the pre-
synaptic and post-synaptic sites (Herkert et al., 1998). In the SP and CP, the 
immunoreactivity for the NMDAR subunits exhibits a radial pattern that corresponds to 
the radial glial fibers and organization of cell bodies in the CP. Moreover, we observed a 
difference in the immunostaining pattern of different subunits. For example, the NR1 
subunit exhibited a more diffuse immunostaining in the VZ compared to the CP, where it  
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looked more punctate (Figure 31A,B), possibly indicating trafficking of NR1 through the 
secretory pathway in the VZ, and membrane expression of NR1 in the CP. This will be 
discussed in detail in the next section of this chapter. Thus, based on NMDAR distribution 
in different cortical cell populations that occupy different zones (Chapter 2), our results 
suggest multiple roles for these receptors during corticogenesis at midgestation. For 
example, presence of NMDAR subunits on RGCs in the VZ, and on Ki67+ cells could 
indicate a role of NMDARs in progenitor proliferation, while expression of NMDAR 
subunits on intermediate progenitors in the oSVZ suggests their role in progenitor 
differentiation, and expression of NMDAR subunits on glutamatergic neurons in the IZ 
could be indicative of NMDAR’s role in neuronal migration. The different age-related 
patterning of expression of NR2B in RGC, intermediate and interneuron progenitors 
suggests a role of this subunit in the specification of cortical progenitors, while NR2A 
containing NMDARs might be important for further neuronal differentiation. Our finding of 
the age-dependent expression of subunits NR2A and NR2B in human fetal cortex 
corroborates with the results of animal studies, and is known to be regulated by synaptic 
activity in rodents (Sanz-Clemente et al. 2013). NR2B-rich NMDARs are found in 
abundance on developing synapses (Yasuda et al. 2011). NR2B-rich NMDARs generate 
slow currents with smaller amplitudes but lasting twice as long compared to NR2A-
mediated current. This allows for a large influx of calcium that promotes gene transcription 
and extends the period of membrane depolarization, which is crucial for generating a 
strong and stable synapse (Yasuda et al. 2011). NR2B is needed at the beginning of 
cortical synaptogenesis; it may be essential for circuitry formation. Many of  
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 these synapses undergo pruning, a process that is dependent on environmental 
experiences, the nature of the stimulus, and age (Rakic et al. 1986; Dumas 2005; Sanz-
Clemente et al. 2013; reviewed in Paoletti et al. 2013). In the adult brain, the strong 
circuitry connections required for long-term potentiation are rich in NR2B- containing 
NMDARs (Tovar and Westbrook 2002; Groc et al. 2006; Sanz-Clemente et al. 2010). 
Experiments using antagonists of the NR2A and NR2B subunits in monkey prefrontal 
cortical slices (Wang et al. 2012) showed that NR2B-type activity on postsynaptic spines 
participates in working memory and learning. Similar results were obtained in mice 
genetically modified to lack the NR2B subunit during their postnatal developmental (von 
Engelhardt et al. 2008). On the other hand, NR2A-rich NMDARs generate the fast 
currents required for strong and transient synaptic connections in response to sensory 
stimuli (Nakagawa et al. 1996; Paupard et al. 1997; Malenka and Nicoll 1999; Malatesta 
et al. 2000). Moreover, NR2A-rich NMDARs occupy synaptic locations as development 
proceeds postnatally in rodents (Malenka and Nicoll 1999; Dumas 2005). This shift from 
NR2B-rich to NR2A-rich NMDARs also occurs postnatally (second week) in rodents, and 
the timing of the switch coincides with the development of associative learning abilities, 
indicating the significance of this process in modifying and tweaking neuronal circuits 
(Dumas 2005; Sanz-Clemente et al. 2013). Thus, in rats reared in the dark without 
appropriate sensory input, the NR2B-NR2A switch in the visual cortex is impaired, but the 
impairment can be reversed by exposing the animals to light (Philpot et al. 2001), 
indicating that the switch is regulated by environmental stimuli, and is plastic in nature. 
Notably, the change in NMDAR subunits is related to the shift from the greater plasticity  
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that characterizes development to the greater stability that marks adult life (Bear et al. 
1987; Kleinschmidt et al. 1987; Constantine-Patton et al. 1990; reviewed in Dumas 2005). 
The NR2B to NR2A switch in NMDAR subunit expression is highly conserved from frogs 
to mammals (Dumas 2005; reviewed in Paoletti et al. 2013), but it has not been widely 
studied in the developing human cerebral cortex (Scherzer et al. 1998; Henson et al. 
2008; Jantzie et al. 2015). 
 
We observed that in the human fetal cortex from 16 to 24 gw, the percentage of 
NR2B-expressing cortical RGCs and neurons decreased, while expression of the NR2A 
subunit increased during the same developmental period of 22-24 gw. These results 
suggest that in human cortical development the switch from NR2B to NR2A begins quite 
early, around 22–24 gw. A larger shift can be assumed to occur postnatally, especially 
between the juvenile and adult stages of development, when cognitive functions mature 
(Dumas 2005; Sanz-Clemente et al. 2013). A more comprehensive picture of the NR2B 
to NR2A switch in human fetal cortex requires the study of a broader range of brain 
tissues of different gestational ages as well as neonatal and adult tissue samples. The 
early distribution of NR1, NR2A, and NR2B in the human cerebral cortex suggests their 
early and distinct roles in cortical progenitor proliferation and specification, and in the 
maturation and synaptogenesis of excitatory and inhibitory neurons in this brain region. 
However, the role of NMDARs in these developmental processes in humans can only be 
speculated upon and not proven. In order to determine if NMDARs are indeed significant 
to processes of cortical development in humans, we established in vitro systems of  
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 primary human cell cultures that mirror the in vivo scenario with respect to cells types 
present in the fetal cerebral cortex. For this purpose, we generated both mixed cell 
cultures from the fetal cerebral cortex that are more representative of the fetal brain tissue, 
and enriched RGC cultures that allow us to ascertain the role of NMDARs in regulating, 
specifically, the cortical multipotent progenitor population. The advance in our thinking of 
the importance of NMDARs in human cortical development comes from in vitro 
experiments performed in Chapters 3, 4, 5. 
  
In vitro systems allowed us to antagonize NMDARs with either its endogenous 
antagonist KYNA (Chapter 3) or its synthetic antagonist D-APV (Chapter 4). These 
studies revealed that NMDARs are involved in progenitor proliferation, specification into 
other progenitor subtypes, and differentiation of progenitors into neurons and astrocytes. 
Moreover, we found that the interneuron progenitor population (Nkx2.1+) and the 
interneuron population (GABA+) are more sensitive to NMDAR antagonism than the 
intermediate progenitor (Tbr2+) and glutamatergic neuron (Tbr1+) cell populations. 
Furthermore, the progenitor differentiation is shifted to astrocyte rather than neuronal 
genesis. To appreciate the changes in cell-type specific populations, the average number 
of cells immunostained for each progenitor and neural cell marker, and the average 
number of total cells, for all KYNA concentrations after 3 DIV of proliferation and 7 DIV of 
differentiation are shown in Table 7. Changes in the average number of cell types during 
cortical development as shown here, can lead to modifications in the development of 
cortical circuits that depend on precise number of neurons and astrocytes as their building  
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blocks. Our data from the concentration-response curves (Chapter 4) indicates that KYNA 
has a higher affinity towards NMDARs than nAChRs. Moreover, our observations on the 
effects of D-APV and KYNA on human cortical progenitors in vitro suggest that KYNA 
acts very similar to D-APV (Chapter 3 and 4). Therefore, elevated levels of KYNA inhibit 
NMDARs that play a significant role in many developmental processes, thereby affecting 
the normal course of corticogenesis in humans.  
 
Our results are in line with observations that elevated levels of KYNA (physiological 
levels are 1 nM) are found in the CSF of schizophrenic patients, as well as in pregnant 
mothers with an activated immune system due to infections with viruses such as Influenza 
type A, and Sindbis virus (Wright et al., 1995). The proposed hypothesis to explain the 
developmental pathology of schizophrenia states that elevated levels of KYNA in the 
maternal serum can activate astrocytes in the fetal brain leading to secretion of pro-
inflammatory cytokines that further induce secretion of KYNA in the fetal brain. This 
feedforward loop of synthesizing more KYNA and aggravation of the immune responses 
in the brain may interfere with the process of brain development, possibly laying the 
foundation for the onset of schizophrenia symptoms in adulthood. Our results show that 
indeed treatment of human cortical progenitors with elevated levels of KYNA (0.01 μM) 
increased the number of reactive astrocytes (S100β+ cells), increased secretion of the 
pro-inflammatory cytokine IL-6, and increased phosphorylation of STAT3, a signaling 
protein downstream of cytokine receptor activation that induces transcription of Gfap,  
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 Table 7 Averaged immunostained cell numbers in KYNA treated cultures 
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3 DIV Proliferation 7 DIV Differentiation 
KYNA 
Treatment 
(48h) 
Cell 
type 
Cell-type specific 
number/ 
total number (BB+ cells) 
Cell 
type 
Cell-type specific 
number/ 
total number (BB+ cells) 
BLBP+ 
98/105  72/111 DMSO 
92/109 
βIII 
tubulin+ 
60/114 0.001 μM 
83/107  45/109 0.005 μM 
76/110  41/112 0.01 μM 
     
Tbr2+ 
27/95  28/136 DMSO 
28/107 Tbr1+ 23/121 0.001 μM 
24/101  21/121 0.005 μM 
21/108  19/114 0.01 μM 
     
Nkx2.1+ 
45/114  59/127 DMSO 
37/111 GABA+ 45/129 0.001 μM 
30/107  37/121 0.005 μM 
23/105  24/110 0.01 μM 
     
GFAP+ 
44/103  42/131 DMSO 
56/118 GFAP+ 57/129 0.001 μM 
71/127  83/125 0.005 μM 
104/129  102/118 0.01 μM 
gene characteristically expressed by astrocytes (Chapter 5). Astrogliosis that we found 
as one of the effects of elevated KYNA in our in vitro system, is also a major anatomical 
observation in brains of schizophrenia patients (Rajkowska et al., 2001). 
 
Future Directions 
NMDAR trafficking 
 
Since the subunit compositions of NMDARs influence the different functional 
properties, the question remains how these complexes are formed and how is their 
distribution regulated? While the NMDAR has been intensely studied with respect to its 
physiology and pharmacology in rodents, its distribution, function, subunit assembly, and 
trafficking, are poorly addressed in human studies. 
 
The NR1 subunit is synthesized in considerable excess (estimated to be about 10-
fold) of NR2 subunit, and the production of receptor complexes is limited by the amount 
of NR2 subunits. Therefore, an increase in the production of NMDAR receptor complexes 
indicates an ongoing synthesis of NR2 subunits (Prybylowski, et al., 2001). A large 
proportion of the glutamate receptor clusters, including NMDARs, in young cortical 
neurons are present on the surface of dendrites before synapses are formed and these 
surface-exposed transport packets are mobile. A large proportion of the transport 
packets, tubulovesicular organelles associated with early endosome antigen 1 (EEA1) 
and synapse-associated protein 102 (SAP102), cycle through the dendritic plasma  
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 membrane before synapse formation (Washbourne et al., 2004). A number of functions 
of the NMDAR are regulated by the multiple intracellular proteins called membrane 
associated guanylate kinase (MAGUKs) like EEA1 and SAP102 that interact with the 
cytoplasmic domains of the NMDAR subunits (Sans et al., 2003, 2005). Such interactions 
in the rodent brain are widely reported in synaptogenesis, and could happen much earlier 
while the NMDARs are still undergoing synthesis, and preparing for trafficking from the 
endoplasmic reticulum (ER) to the plasma membrane (Hawkins et al., 2004). Identifying 
the specific MAGUKs that govern the subunit assembly and trafficking of NMDARs will 
enable us to identify the NMDAR subunit composition in development. This might play a 
role in the developing neuron when NR2B is replaced by NR2A as the predominant 
subunit leading to a functional change that produces a receptor with faster kinetics and a 
tendency to be more synaptic than extra-synaptic (Kohr, 2006; Groc et al., 2004). Since 
the subunit composition of NMDARs dictates its functional properties, drugs specific to 
subunits can be used to study the significance of each subunit in coritcal developmental 
processes, and can help in furthering our understanding of the NR2B-NR2A switch. It 
should also be noted that the NR1 subunit can assemble with the NR3 subunit to produce 
a functional glycine receptor (Perez-Otano et al., 2001; Matsuda et al., 2003).  
 
Trafficking of NMDARs employs MAGUKs and depending on the cellular activity, 
NMDARs can undergo a full cycle of exocytosis and clathrin-dependent endocytosis 
during transport (Roche et al., 2001).  Enhanced forward trafficking from the ER to the 
trans-Golgi network (TGN) results in an increased co-localization of NMDAR subunits  
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with the cis-Golgi marker GM130 (Tovar and Westbrook, 1999; Li et al., 2002). GM130 is 
a members of the Golgin family of proteins and plays significant roles in establishing and 
maintaining Golgi structure and transport (Barr and Short, 2003), ensuring uniform 
distribution of Golgi enzymes (Puthenveedu et al., 2006), facilitating ER-Golgi transport, 
and is implicated in signal transduction regulating invasion, migration, and cell 
polarization via its interaction with serine/threonine kinases (Preisinger et al., 2004).  
 
Based on these observations, we performed preliminary experiments to identify if 
NMDAR subunits NR1, NR2A and NR2B undergo a similar trafficking mechanism in 
human cortical development. This idea came from a difference in the immunostaining 
pattern of different subunits. Immuno-reaction for the NR1 subunit is more diffuse in the 
VZ (Figure 31A), and punctate in the CP (Figure 31B). As a preliminary study, we co-
labeled the NMDAR subunits with the cis-Golgi marker GM130 in cryopreserved coronal 
sections of the 18 gw human fetal brain. Our results were similar to that observed in 
transfection studies in rodents where all three subunits were localized within the 
intracellular organelles (McIlhinney et al., 1998). We observed that in the proliferative VZ 
the NMDAR subunits NR1, NR2A and NR2B co-localized with GM130, not only in the cell 
body, but also along the processes of progenitor cells (Figure 32A). This pattern was, 
however, different in neuronal cells in the CP, where highest amounts of co-localization 
was observed along the cell processes (Figure 32B)., suggesting that NMDAR subunits 
have completed ER processing, and are moving along the forward-trafficking path in the 
VZ and CP at 18 gw.   
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Figure 31. Immunohistochemistry for NR1 subunit at 18 gw. Immunostaining pattern 
appears diffuse in the VZ (A), and punctate in the CP (B). Nuclei are stained with BB. 
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Figure 32. NMDAR subunits are present in the Golgi network in the human fetal brain at 
18 gw. Immunohistochemistry with NMDAR subunits NR1, NR2A and NR2B (green) 
shows co-localization with the cis-Golgi marker GM130 (red) in the proliferative VZ (A) 
and in the neuron-rich CP (B). 
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 Future studies involving triple-immunolabeling with primary antibodies against NMDAR 
subunits and anti-GM130 antibody, will enable us to examine the trafficking of subunits 
during development of the human cortex.  Also, co-localization studies of the NMDAR 
subunits with clathrin would entertain the possibility of endocytosis of specific subunits 
during synaptogenesis in humans. This would enable us to observe if NR2Bsubunits are 
endocytosed post-midgestation (~22 gw) resulting in their reduced expression with 
increasing age. Furthermore, the phosphorylation status of various intracellular MAGUKs, 
specifically, SAP102, and PSD-95, would be interesting to explore. Both of these 
molecules have high binding affinities to the PDZ domains present on the cytoplasmic C-
termini of the NR1 and NR2 subunits. Association of these MAGUKs with NMDAR 
subunits could indicate the assembly of receptor complexes in the ER, as well as identify 
the specific MAGUKs associated with the NMDAR subunits at the plasma membrane 
during human corticogenesis. 
 
NMDAR physiology 
 
NMDARs require simultaneous agonist and co-agonist binding, and membrane 
depolarization to open the channel pore, which remains blocked by magnesium ions at 
resting membrane potentials (Mayer et al., 1984; Nowak et al., 1984). The role of 
NMDARs has been most widely studied by blocking the ion flux through these receptors 
using pharmacological agents such as D-APV, a competitive antagonist of the glutamate-
binding site on NR2; 7-chlorokynurenate, or 7-CK, a competitive antagonist of the co- 
201 
agonist site on NR1 (7-CK is an early derivative of the naturally occurring KYNA, which 
is a non-selective antagonist of NMDARs as well as the α7nAChR); MK-801, an 
uncompetitive blocker of the channel pore (Zito and Scheuss, 2009). NMDARs function 
as ion channels mediating the influx of extracellular calcium, a secondary messenger 
involved in signal transduction pathways, and in regulation of gene expression 
(Hardingham et al., 2001).  
 
Recent studies have provided provocative evidence suggesting NMDARs ability to 
signal in the absence of ion flux through its channel pore (Dore et al., 2015).  It is 
hypothesized that agonist binding to the NMDAR causes conformational changes in the 
cytoplasmic domain of the receptor subunits via a non-ionotropic signaling mechanism 
independent of channel opening that induces a conformational change in the 
transmembrane segments of the receptor subunits (Tamburri et al., 2013; Aow et al., 
2015; Stein et al., 2015). Indeed, Dore et al. in 2015 demonstrated that binding of the 
specific agonist NMDA to the glutamate site on the NR2 subunit led to conformational 
changes in the NMDAR intracellular domains in the presence of 7-CK and MK-801, but 
not in the presence of D-APV, providing evidence for agonist-induced, but ion flow-
independent, conformational changes in the NMDAR C-terminal tails. This new 
knowledge of NMDAR-mediated signaling, if proven true, can entice an exciting new era 
that challenges the current understanding of synaptogenesis and synaptic plasticity.   
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Figure 33. (A) Control human RGC cultures incubated with calcium indicating dye OGB1-
AM. The red traces indicate possible electrical activity-dependent calcium transients. (B) 
Calcium recordings performed on KYNA treated RGC cultures. Calcium transients seen 
in normal saline (first panel) indicate that these cells are undergoing a change in 
intracellular concentration. The calcium transients remain unaffected by NMDAR 
antagonist D-APV (middle panel), but they decrease upon Ryanodine application (last 
panel).  
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Activation of NMDARs independent of ion flux through its channel pore is an 
important mechanism that induces endocytosis of NMDARs (Vissel et al., 2001), as well 
as phosphorylation of extracellular signal-regulated kinase (ERK) and increased c-Fos 
expression (Yang et al., 2004). Non-ionotropic NMDAR-mediated signaling through Src 
kinase is also central to pathological processes that lead to neuronal death during 
excitotoxicity (Weilinger et al., 2016). In addition to glutamate, co-agonist binding to the 
glycine site on the NR1 subunits may also be involved in non-ionotropic signaling, as 
glycine binding has been found to prime the NMDAR for subsequent clathrin-mediated 
endocytosis in the presence of D-APV but not glycine site antagonists like KYNA (Nong 
et al., 2003). 
 
Human fetal RGCs and other cortical progenitors, possess excitable membranes 
and can generate abortive action potentials upon receiving a current stimulus (Howard et 
al., 2008). In rodents, progenitor cells in the VZ possess large calcium waves (Weissman 
et al., 2004). These functions are intricately tied to the predisposition of progenitors to a 
neuronal lineage, and maturation of young neurons. The large calcium transients, have 
in most cases, been fueled by the intracellular calcium stores. This is evidenced from 
studies showing that large calcium transients are abolished upon application of IP3 
receptor blockers or Ryanodine (Weissman et al., 2004). In light of the previous studies, 
we tested our human RGC cultures for the presence of calcium activity that was NMDAR-
dependent. It is important to identify if developmental processes depend on NMDARs 
ability to transport calcium ions through the channel’s pore and how KYNA affects this  
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 NMDAR feature. If calcium activity in RGCs is detected and is non-NMDAR dependent, 
then we need to understand the mechanism through which KYNA affects intracellular 
calcium concentrations, since calcium is an important secondary messenger involved in 
the transcription of many developmental genes including Tbr1 (Kristiansen et al., 2010). 
 
 As a preliminary experiment, we incubated our control RGCs and KYNA treated 
(0.01 μM) RGCs, with a light excitable calcium indicator Oregon Green BAPTA 1- 
Acetoxymethyl (OGB1-AM) for 30 min at 37oC. Oregon Green is a dye that is excited by 
the blue wavelength (480 nm) and emits fluorescence in the green wavelength (520 nm) 
in the visible range of the electromagnetic spectrum. AM allows this dye to diffuse across 
an intact plasma membrane, and is cleaved by intracellular esterases that prevents the 
diffusion of dye out of the cell. BAPTA is a potent calcium chelator, and when calcium 
binds to OGB1-AM, a conformational change occurs in the structure of this dye allowing 
it to fluoresce green. We applied the calcium imaging protocol to our cell cultures 
incubated with OGB1-AM in the Antic laboratory at UConn Health. We found that human 
RGCs exhibit spontaneous calcium transients (Figure 33A), and some of these were 
indicative to be dependent on the electrical activity of the cells (Figure 33A; red traces). 
The presence of fast calcium transients resembling action potential mediated calcium 
transients in neuronal lineage has four potential explanations: 
1. Our cultures contained cells of neuronal lineage on the day of the experiment (3 
DIV of proliferation). 
2. Though highly unlikely, it is possible that human RGCs exposed to postmortem  
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handling followed by several days in culture begin to exhibit some electrical excitability 
and fire spontaneous action potentials. This idea that RGCs fire action potentials needs 
to be demonstrated in acute brain slices, by patching RGCs with dye-filled electrodes.  
3. We are dealing with a specific form of calcium internal release characterized by 
small amplitude and narrow duration.  
4. We may have sick cells in culture. These injured cells may produce pathological 
transients. Instead of big and wide (Figure 33A, white traces) the unhealthy transients are 
small and narrow. 
 
The following experiments need to be performed in the future to resolve the origin 
of small-amplitude narrow-duration calcium transients.  
Experiment 1: Human RGCs need to be re-cultured and controlled optical 
measurements will need to be made (Figure 33A), followed by bath application of sodium 
channel blocker, tetradotoxin (TTX). If sharp calcium transients are action potential 
mediated, then TTX would eliminate them. 
 Experiment 2: Control optical measurements (Figure 33A), followed by bath 
application of potent inhibitors of the sarcoplasmic reticulum calcium-ATPases such as 
thapsigarging and cyclopiazonic acid needs to be done. If sharp calcium transients are 
mediated by action potentials and wide calcium signals are mediated by internal release, 
then bath application of thapsigarging and cyclopiazonic acid would eliminate wide 
transients and spare the narrow ones.  
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 Moreover, calcium transients in Figure 33B (second panel) remained unaffected in 
the presence of D-APV, but were reduced in number and amplitude upon addition of 
Ryanodine (Figure 33B; fourth panel). There can be three justifications for this 
observation:  
 
1) Since KYNA had already compromised the function of NMDARs, these receptors could 
not pass calcium through, and therefore, no change was observed in the calcium transient 
profile upon D-APV addition. It further suggests that the initial calcium transients seen in 
KYNA-treated cells were due to the release of calcium from intracellular stores consistent 
with observations after Ryanodine application (Figure 33B).   
 
2) Due to KYNA treatment there could be increased NMDAR endocytosis and less 
number of functional NMDARs present at the cell surface to exhibit NMDAR-dependent 
calcium activity. It would be interesting to study if KYNA triggers NMDAR endocytosis. 
 
3) Based on our new knowledge that NMDARs can function in an ion-independent 
manner, the calcium activity we see in our control RGCs could be from calcium influx 
through gap junctions or hemichannels, expression of which have been shown in young 
human neuronal cultures (Belinsky et al., 2014).  
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